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ABSTRACT 
Cancer remains one of the most feared diseases affecting the modern world.  Second to heart disease, it is 
the largest cause of deaths, affecting one in three persons.  Cancer cells are formed when normal, healthy 
cells become damage, losing their normal regulatory mechanism that control cell growth.  There are many 
different types and progression of these cancer cells that determine the type of treatment a patient receives.  
The primary focus of this dissertation is to propose three studies of anticancer agents.  In Chapter one, a 
CpG-lytic peptide conjugate was designed to target receptors on the cell membrane to concentrate the lytic 
peptide around the cells to cause triggered cell death, in the treatment of Myelodysplastic Syndromes 
(MDS).  This conjugate act like monoclonal antibodies in that the molecular size is too large to enter the 
cell, therefore it targets the TLR9 receptors expressed extracellularly in precancer cells in MDS.  Chapter 
two, focuses on the screening of anticancer agents used in targeted therapy.  It provides a general scheme 
applied to the synthesis of a combinatorial library of primary amines used as small-molecule drugs coupled 
unto a solid support bead (Positional Scanning Library Method) to screen for biological effects on various 
types of cancers.  Chapter three address the issue of radiotherapy treatments, one of the most widely used 
treatment of cancer.  To improve the efficacy of conventional radiation therapy and reduce the cytotoxicity 
of healthy tissue, High-Dose Rate brachytherapy (HDR) may be used as a stand-alone treatment or after 
surgery to prevent the recurrence of cancer cells.  To design and provide studies of these brachytherapy 
beads, a model was developed by coupling a chelating agent DOTA onto the surface of macrobeads that 
coordinated to Europium (III) in efforts to mimic the radiolabeling with a radioactive metal.  These 
brachytherapy beads will be used to conduct in vitro studies in the treatment of local cancers with massive 
concentrations of radiation without damaging surrounding healthy tissue.
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CHAPTER ONE: 
INTRODUCTION  
 
1.1 General Overview of Cancer 
Cancer, a disease in the modern world that is a growing public health concern that requires 
prioritization, awareness and funded research.  According to the World Health Organization, it is the second 
leading cause of deaths globally, after heart disease, causing 8.8 million cancer-related deaths worldwide 
in 2015.1 The annual number of new cases is projected to climb from 14.1 million in 2012 to 21.6 million 
in 2030.  Cancer is a collection of more than 200 diseases that originates in a change of one cell in the body 
or a group of cells caused by a mutation of the genes when the cells divide1-3.  The mutation causes normal 
cells to lose their regulatory mechanisms that control cell growth and multiplication, becoming “rouge 
cells”.  This causes a loss of differentiation – losing their specialized characteristics that distinguishes one 
type of cell from another.  These defective cells may divide uncontrollably to form a lump known as a 
tumor, where the site of origin is the primary tumor and terms the type of cancer.  If the cancer is localized 
it is said to be benign; however, if it invades other parts of the body triggering a cascade of secondary 
tumors – metastasis – the cancer is termed as malignant.  Some types of cancer, known as leukemia, start 
in the blood cells and builds up in the blood and bone marrow; they do not form tumors.  
 Depending on the type of cancer a patient has and how advanced it is, will determine their course 
of treatment.  Typically, most patients would undergo one type of treatment but are not limited to surgery, 
chemotherapy and/or radiation therapy.  Other types of treatment are targeted, immunotherapy, stem-cell 
transplant, hormone therapy, and precision medicine cancer treatment.  Targeted therapy and radiation 
therapy were the primary area of focus in the treatment of cancer throughout this dissertation.    
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 Targeted Therapy.  This type of cancer treatment uses small molecule drugs or monoclonal 
antibodies to specifically target the change in the cancer cell that helps them progress.  One of the 
advantages, unlike surgery and radiation therapy, is its ability to target cancer cells that have metathesize 
far from the primary area of the tumor by targeting a protein or gene expressed in the cell or on the outer 
cell surface.  Much research is carried out to determine which biomacromolecules are involved in the 
survival of the disease.  This information leads the development of a drug which produces a biological 
effect.   
 Radiation Therapy.  This is another course of treatment of cancer that uses high-energy radiation 
to reduce the size of tumors and eradiate cancer cells by damaging their DNA.  X-rays, gamma rays and 
charged particles may be delivered by an external bean of radiation from a machine, or may be injected into 
the body at the site of the cancer cells and delivered by radioactive material (also known as Brachytherapy).  
Typically, about 50% of patients receive some type of radiation therapy during the course of their treatment.  
1.2 Oligonucleotides 
Oligonucleotides are short chain, single stranded oligomers that are being used as therapeutic 
potential agents in cancer treatment.  They are made up of nucleotide monomers – building blocks of 
biological polymers – deoxyribonucleic acids (DNA) and ribonucleic acids (RNA), composed of three main 
subunit molecules, a five-carbon sugar, ribose in RNA or deoxyribose in DNA, a nitrogenous base, and at 
least one phosphate group.   
The nuclei acids, DNA and RNA, are differentiated by their bases and the 2` carbons as seen in 
Figure 1.1.  In the laboratory, these fragments of nuclei acids are synthesized as single-stranded molecules 
by solid-phase synthesis, the Phosphoramidite method, where one nucleotide is added per synthesis cycle 
in a 3'- to 5'-terminus (opposite to the 5′- to 3′-direction of DNA biosynthesis in DNA replication) forming 
phosphate ester linkages.  Firstly, the 3`-OH of a DMTr-protected monomer at its 5`-OH is activated with 
a phosphoramidite group.  Under the agency of a suitable activator and subsequent hydrolysis, the 
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monomers are connected in a sequential pattern creating a backbone of sugar and phosphate units which 
undergo oxidation to increase the stability of the growing oligomer in accordance with other chemical 
processes.  
 
Figure 1.1. Structural elementals in a nucleotide. Highlighting in yellow the phosphate group, in blue the numbered 5-membered 
sugar ring for DNA and RNA, and in grey the nitrogenous base.  At upper right the purine bases, adenine or guanine, and pyrimidine 
bases, cytosine and thymidine where in RNA, the thymidine is replaced with uracil.                   
 
Figure 1.2. General synthesis scheme of a fully protected deoxynucleotide 3` cytosine-phosphoramidite and iBu protected guanine 
attached to solid support at 3`O, forming a CpG dinucleotide.  
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In vitro studies indicated synthetic oligodeoxynucleotides containing unmethylated CpG 
dinucleotides within their sequence, in conjunction with lytic peptides, have potent immunostimulatory 
effects and can enhance the anti-cancer activity of a variety of cancer treatments, more specifically.  There 
are, however, disadvantages to the use of oligonucleotides as drugs, as they are rapidly degraded by 
nucleases enzymes.  Also, they are large and highly charged which hinders the absorption through cell 
membranes.  Therefore, attempts to stabilize these molecules and to reduce their polarity have involved 
modification of the phosphate backbone and masking the primary amines on their bases.     
1.3 Peptides 
Parallel to Oligonucleotides, Peptides are polymers with repeating monomeric units called amino 
acids, and are used as therapeutic agents that have shown enhanced bioactivity.  Peptides are distinguished 
from proteins based on size and structure, typically containing fewer than 50 monomers.  Each amino acid 
consists of an N-terminus and C-terminus apart from cyclic peptides.  The N-terminus of an amino acid is 
covalently bonded to the C-terminus of another to form a peptide or amide bond.  The stability of the peptide 
bond is due to the planar C=O and N-H bond having partial double-bond character due to resonance – the 
delocalization of electrons over several atoms – which restricts free rotation around the bond and increases 
the polarity of the peptide bond, as shown in the Figure 1.3.   
 
Figure 1.3. Dipeptide molecule of two L-amino acids highlighting amide bond and chiral centers at the Cα showing resonance of 
the partial double bond character.  
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Peptides typically consist of a primary structure composed of up to 20 different naturally occurring 
L-α-amino acids.  All proteinogenic amino acids possess common structural features, a chiral α-carbon 
center to which an amino group, a carboxyl group, and a variable side chain which determines the physical 
properties of the amino acid, are bonded.  The chirality of all naturally occurring L-amino acids, apart from 
glycine and cystine, has the S configuration.  The R side chain of Glycine being a hydrogen atom takes 
away the chirality at the Cα, whereas L- cystine has an R configuration at its Cα due to the Cβ attached to 
the sulfur atom having higher priority than the carbonyl carbon.   
 
Figure 1.4. L-cystine (left) R stereochemistry and L-alanine (right) S stereochemistry 
Chirality in peptides plays a crucial role in drug design and development.   In designing of small 
molecule peptides to interact with enantioselective targets, the stereoselectivity must be considered as the 
binding affinity for a chiral drug differ for diastereomers and between enantiomers.  It is also factored in 
during the virtual screening and computation design stage of drug development.  By being more 
stereoselective may lead to a compromise between exploration of a vast possibilities of chemical space and 
maintaining an exponential increase in the number of structures resulting in potentially unmanageable file 
sizes and screening times.   
The properties of the peptide bond account for several crucial properties of peptides in aqueous 
conditions.  Firstly, the dipole moment of each peptide bond increases the solubility of the peptide.  
Secondly, the combination of free rotatable single covalent bonds about the N–Cα and Cα–C and the 
alternating rigid coplanar peptide bonds greatly restricts the number of possible conformations that the 
peptide chain can adopt.  This makes it possible to predict from simple steric studies the most likely 
backbone conformation angles and interactions with its target.  This serves it as a suitable drug candidate.  
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Figure 1.5.  Primary structure of tripeptide showing free rotation about the N–Cα and Cα–C. 
1.4 Solid Phase Synthesis 
Solid-phase methods have been industrialized to allow for large scale synthesis of oligonucleotides 
and peptides that are used as drug molecules.  In 1959, Bruce Merrifield postulated that if a peptide is 
chemically bound to an immobilized, insoluble support by simply removing any unreacted reagents using 
a solvent wash reduces the time required for purification and synthesis of the desired polymer.  Solid-
support synthesis became a paramount in the field of Biochemistry, which awarded Merrifield the Nobel 
Prize in 1984.  Today, solid-phase synthesis is extensively used by organic chemist to synthesis peptides, 
oligomers and complex molecules that pose to be challenging using solution-phase synthesis.   
Solid supports are polymeric resin beads to which a linker is attached that provides the area of 
support to which the growing polymer is chemically bonded.  Contingent on the biomolecule being 
synthesized and the conditions required, the type of support chosen is dependent on the properties of the 
resin, the size of the beads (80-200 µm), mesh size – the number of openings per square inch (70-170), 
mechanical and thermal stability and price.  Common resins used are Cross-linked-Polystyrene, Polyamine, 
Tentagel and Soluble Resins, where the loading efficiency is determinant on the solvent used to swell the 
resin necessary for diffusion and accessibility of active sites.   
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Figure 1.6.  Representation of cross-linked polystyrene resin after swelling in solvent unmasking the active sites.   
Many types of resins have been used in oligodeoxynucleotide synthesis but controlled pore glass (CPG), 
polystyrene and Tentagel have proven to be most efficient.  As described in Chapter 2, TentaGel® HL OH 
resin was used for its ability to carry out reactions in aqueous conditions and for its lower substitution level.  
Oligodeoxynucleotide synthesis at higher loadings becomes less efficient due to steric hindrance between 
adjacent DNA chains attached to the resin18.  The schematic outline of the Phosphoramidite method is 
described in Figure 1.7. The oligodeoxynucleotide is assembled onto the solid support by a stepwise 
addition that firstly requires deprotection the 5`-Dmtr protecting group of the support bound nucleoside, 
detritylation.  The role of this protecting group is to prevent polymerization during the coupling step and is 
also useful due to its orange color that can quantitatively determine the coupling efficiency.  The purine 
and pyrimidine bases, apart from Thymidine, are protected as well to avoid cyanoethylation side reactions.  
Subsequently to detritylation, the support-bound nucleotide is coupled with an activated nucleoside 
phosphoramidite monomer in the presence of a weak acidic catalyst.   
The coupling step isn’t 100% efficient, and there maybe a few unreacted 5`hydroxyl groups on the 
resin-bound nucleoside that would be available to couple with the next phosphoramidite monomer.  This 
would result in multiple chain growth that would be difficult to purify.  Therefore, it is necessary to employ 
a capping step after each coupling that acetylates the free OH group. 
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Figure 1.7. The phosphoramidite oligodeoxynucleotide synthesis cycle. 
 
 The phosphorus atom of the phosphite-triester formed after coupling, has an oxidation state of +3 
and is unstable to acid and must be oxidized to +5 prior to next detritylation step.  This iodine oxidation 
method, stabilizes the DNA backbone which is also protected with the cyanoethyl group that prevents 
undesirable reactions at the phosphorous atom.  An additional capping step is useful to dry the resin after 
oxidation to remove any persistent water molecules that will inhibit the next coupling reaction.  The cycle 
is then repeated until the desired length is achieved and the oligomer is cleavage from the resin and purified.  
It is important to note that the resin is washed with aprotic solvents in between each step.   
Solid-Phase Peptide synthesis (SPPS) share some general schematic comparisons to that of 
oligodeoxynucleotide synthesis.  The protected amino acids are assembled stepwise onto the resin in a C- 
to N-terminus direction on an immobilized solid support that affords purification of the growing peptide at 
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each step.  The amino acids are also protected at the N-terminus and side chains with appropriate protecting 
groups based on the reaction conditions, final peptide and other additional molecules attached to the peptide. 
Fmoc and Boc chemistry are widely used strategies in both solid and solution phase peptide synthesis in 
protection of the N-terminus of amino acids.  Boc limitations of extremely hazardous and corrosive 
chemicals for the deprotection step have awarded the Fmoc group to be vastly use for peptide synthesis 
since it is more chemically compatible with commercially available peptide synthesizers.   
There are several factors to consider when choosing the appropriate resin for the synthesis: 
procedures used for the coupling of the first amino acid residue to ensure a racemization-free attachment, 
cleavage conditions and the final peptide C-terminus functionality.  The same can be said for the coupling 
agent used in the activation on the C-terminus.  Over the years, there have been numerous carbonyl 
activation methods developed to improve the electrophilicity of the carbon atom: generation of the acid 
chlorides or fluorides, symmetrical or mixed anhydrides, activated esters or azides, Uronium based coupling 
reagents and the use of carbodiimides (DCC, DIC, EDC.HCl), with or without racemization suppressants.  
Carbodiimides have been the preferred activation reagents for decades despite the challenges faced during 
purification methods.  These reagents produce a by-product urea that have varying solubility in the solvents 
used in SPPS.  EDC urea is water soluble and is easily removed with an aqueous wash, however can be 
costly especially since it is used in excessive amounts.  DCC and DIC are more cost-effective reagents, but 
DCC is a known allergen and skin irritant often causing skin rashes, and the urea formed is only partially 
soluble in many organic solvents.  DIC is a liquid, easier to handle, and its urea by-product is more soluble 
in organics and therefore is the preferred carbodiimide activating reagent.  However, in recent years two 
new classes of coupling reagents became popular, the phosphonium- and the aminium-(imonium-) type 
reagents, for example BOP, PyBOP, HBTU, HCTU to name a few.  In the presence of an organic base, 
these compounds are known for their high coupling rates, fewer undesired side products, and     
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 Figure 1.8. Common carbodiimides used in SPPS as activators of the C-terminus group. 
 In SPPS the Fmoc protected α-amino acid is activated in situ and coupled to the resin in the presence 
of a weak base such as DIEA and a racemization suppressant, HOBt.  The resin is washed with a polar 
aprotic solvent and the Fmoc is removed and the cycle continues until the desired length of monomers.  The 
SPPS generalized scheme is outlined in Figure 1.9. 
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Figure 1.9.  A generalized scheme of SPPS showing the main steps of activation, deprotection and coupling 
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1.5  Peptoids  
Peptides have been considered potential therapeutic drugs that possess many advantages over small 
molecule and biologic drugs due to the better binding efficiency to their target, higher specificity, and lower 
toxicity.  While peptides are relatively inexpensive to synthesize, and their short length allows them to 
adopt multiple conformations that mimic portions of proteins or small molecule, their susceptibility to 
proteolytic cleavage and therefore short half-life in the body incumber peptides from being favorably drug 
candidates.  In efforts to overcome these challenges, researchers have employed promising peptidomimetic 
compounds called Peptoids.      
Peptoids, also referred to as poly-N-substituted glycine, were first invented by Reyna J. Simon, 
Paul Bartlett and Daniel V. Santi to be used as protein/peptide mimics in drug discovery scaffolds.  This 
new class of polymers are synthetically accessible and have shown significant biological activity and 
proteolytic stability.  Unlike peptide monomers whose side chains form a chiral center at the α-carbon, the 
R group replaces the amide proton of the amino group resulting in no stereogenic centers in peptoid 
monomers.         
 
Figure 1.10. Structure showing a fragment of a peptide compared to a peptoid. 
The structure modification of a peptoid limits the formation of the α-helical and β- sheet secondary structure 
found naturally occurring in peptides due to the lack of hydrogen bonding and therefore denaturing factors 
such as urea, temperature and solvent do not pose a threat.  Additionally, peptoids have been developed as 
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drug candidates for a wide range of different biomedical applications, including antimicrobial agents and 
synthetic lung surfactants. 
 Peptoids are perfectly valuable to build combinatorial libraries, primarily because they can be 
synthesized easily from commercially available primary amines that are relatively inexpensive.  Major 
advantages in screening methodologies, for example the positional scanning library, have facilitated for 
peptoid libraries of hundreds of thousands of compounds to be screened cost effectively and quickly for 
high specific protein-binding molecules.    This approach is further discussed within Chapter 3 – a simple, 
cost-effective scheme developed to synthesize peptoid monomers with varying R-CH2- groups used in 
combinatorial library high-throughput screening. 
1.6 Radioactivity 
The emission of subatomic particles or high-energy electromagnetic radiation by the nuclei of 
atoms was discovered in 1896 by Antoine-Henri Becquerel in 1896, and was termed Radioactivity.  The 
different types of radioactive elements were further developed by Marie Curie.  Such radioactive nuclei are 
unstable and spontaneously decompose emitting fragments of the element to gain stability, that are 
categorized into several types, alpha (α) and beta (β) decay, gamma (γ) ray and positron emission.  Some 
unstable atomic nuclei can absorb an electron from one of the atom’s own orbitals, known as electron 
capture.  Radioactivity play an immense part in Medicine in the treatment of tumors in which the use of 
alpha particles is further explained in Chapter 4. 
Alpha particles are helium-4 atoms emitted from the parent nuclide resulting in a daughter atom 
that have two protons and neutrons less, a decrease in atomic number by 2 and mass number by 4 as shown 
in Figure 1.11  
 
Figure 1.11. Picture illustrating the release of a helium-4, alpha (α) particle from a radioactive element. 
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Most recently, in May 2013, the FDA approved the first cancer treatment drug containing an alpha-
emitting isotope.  Prior to this, radioactive isotopes used in endoradiotherapy – a form of radiation therapy 
in which a radioactive substance is ingested or injected into the patient – were β emitters (electrons or 
positrons).  In cases of sizeable tumors that are isolated to an area in the body, surgery is the best option.  
However, chemotherapy is a viable choice for small groups of cancer cells that have metastasized.  
Endoradiotherapy drugs can be engineered to offer an alternative, more localized treatment, to 
chemotherapy by releasing β-particles to destroy cell DNA by ionizing other atoms and releasing chemical 
species in the cells.  Interestingly, α-particles have the same therapeutic effect and are more direct in 
delivering larger amounts of energy to the cancer cells and disrupting chemical reactions, making them 
more cytotoxic than β-emitters.     
1.7 Characterization methods 
Liquid Chromatography – Mass spectroscopy (LC/MS), Nuclear Magnetic Resonance (NMR), and 
Matrix Assisted Laser Desorption/Ionization (MALDI) were techniques used as characterization techniques 
during this study.  The progress of the solution phase reactions was monitored by Thin-Layer 
Chromatography (TLC).    Preparatory High-Performance Liquid Chromatography (HPLC) methods were 
used to purify the lytic peptide.  
TLC is a relatively inexpensive chromatography technique used to monitor the course of a reaction 
and to some extent, the purity of products being formed.  This analytical technique comprises of two phases: 
a stationary phase and mobile phase.  The stationary is a thin layer of adsorbent silica gel, aluminum oxide, 
or cellulose coating a thin sheet of glass, aluminum foil or plastic onto which the nonvolatile compounds 
are spotted and travel.  The mobile phase comprises of a solvent or solvent mixture (eluent) in different 
combinations dependent on the desired polarity.  The mobile phase is used to separate the compounds 
formed in the reaction mixture based on its affinity to the stationary phase as the eluent travels up the plate.  
The compounds can be identified based on their Retention Factor (Rf) that represents the distance traveled 
by the analyte over the distance traveled by the solvent.  The greater the Rf value, the more nonpolar the 
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compound, and the smaller the Rf value the greater affinity the compounds have for the stationary phase.  
This technique can be used to determine the absence of the starting material to confirm the completion of a 
chemical reaction.  Analytes containing chromophores can be detected under short-wave UV light using 
fluorescent plates.  In the cases of non-UV active compounds, the plates can be developed in an Iodine 
chamber containing a mixture of Iodine crystals and silica gel or in the presence of a primary amine, the 
plate can be stained with Ninhydrin.  This staining technique was useful in the synthesis of primary amines 
in Chapter 3.  
Mass Spectroscopy is a powerful analytical technique used for studying the masses of atoms, 
molecular fragments and molecules that comprises of three main methodologies – ionization, ion separation 
methods and representation – used to elucidate the molecular weight of a compound based on their mass-
to-charge ratio (m/z).  The analyte is ionized dependent on the ionization source, the ions are accelerated 
by an electrical field and separated based on their m/z and the number of ion units is represented as a 
spectrum.  Commonly used is Electron Impact (EI) ionization where the analyte molecules are placed under 
high vacuum, vaporized and bombarded with a beam of high-energy electrons.  This dislodges one of the 
valence electrons forming a radical cation (Molecular Ion, M+) that may impart so much energy that the 
molecule can be further fragmented into additional ions.  The molecular ions are then deflected by a magnet 
as they travel through the analyzer tube toward a detector which are recorded as a spectrum of the signal 
intensity along the y-axis versus m/z along the x-axis.  The signal intensities are representative as a 
percentage of the most intense signal called the base peak. 
Liquid Chromatography-Mass Spectroscopy (LC/MS) encompasses the physical separation 
capacities of liquid chromatography and the mass analysis of mass spectroscopy that can be used to 
elucidate the structural formula of unknown compounds based on the ion fragments.  LC/MS draws many 
similarities to High Performance Liquid Chromatography (HPLC) – the sample is carried along by the 
eluting liquid (mobile phase), pH-adjusted water-organic mixtures, at high pressure through a nonpolar 
stationary phase, typically octadecylsilyl (C-18 column).  The sample is injected into the continuous solvent 
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flow and travels through the analytical column and the compounds are separated based on their affinity to 
the stationary and mobile phase.  In LC/MS, the components in the sample are passed through a mass 
detector in a response time it takes for the compounds to pass from the injector to the detector known as the 
retention time. LC/MS is a highly sensitive, more accurate and specific assay procedure compared to that 
of HPLC which is useful for preparatory purification of biomolecules.   After purification the molecular 
weight is determined by a nondestructive ionization of the compound using Matrix-Assisted Laser 
desorption/Ionization.  MALDI-TOF Mass Spectrometry is a soft ionization technique in mass 
spectroscopy, compared to LC/MS, used for rapid, multiple sample analysis to characterize high molecular 
weight molecules such as peptides and oligonucleotides.  It is a highly sensitive, computer- controlled 
procedure used to monitor ion signal as a function of laser position and intensity.  An aliquot of the purified 
sample is uniformly mixed with an excess of the matrix (a solution of an ultraviolet (UV) absorbing 
compound) and spotted onto the plate.  The liquid evaporates leaving dry crystals on the plate.    A nitrogen 
laser light irradiates the mixture and causes the matrix to absorb UV A light converting it to heat energy 
and a small amount of the matrix rapidly heats up assisting in the volatilization and ionization of the analyte.  
The ions produced are analyzed using time-of flight (TOF) mass spectrometer.  TOF-MS separates ions of 
similar kinetic energy but different m/z since lighter ions travel faster that heavier ones.  The pattern of the 
fragmented ions and their isotopic peaks help elucidate the structure of organic molecules.   
Another characterization technique is Nuclear Magnetic Resonance (NMR), absorption 
spectrometry in which a sample is placed in a magnetic field and absorbs electromagnetic radiation in the 
radio frequency region at frequencies dependent on the characteristics of the sample and strength of the 
field and the magnetic properties of the isotopic nuclei.  The NMR spectrum constitutes the frequencies of 
the absorption peaks versus peak intensities.  This tool is used to study the molecular energies and structure 
of compounds containing certain nuclei, such as 1H, 13C, 3H, 15N, 19F or 31P.  These nuclei have spin numbers 
I of ½ and a uniform spherical charge distribution behaving as magnets spinning about an axis.  When they 
are placed in a strong magnetic field and subsequently irradiated with radiofrequency radiation, the nuclei 
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absorb energy and transition into energy levels that is quantized, and a spectrum can be recorded.  This 
process is known as magnetic resonance.  Valuable information about a molecular structure can be provided 
from the NMR spectrum.  The number of signals and their positioning can determine the number of different 
types of protons and their magnetic environment, respectively, arising from the electron density in their 
environment, i.e. whether there are near electron donating or withdrawing groups.  The area under the 
signals, known as the integration, calculates the number of protons and the splitting of the peaks elucidates 
the number of adjacent protons to the one whose signal is being measured.             
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CHAPTER 2 
SOLID SUPPORT SYNTHESIS OF A CPG-LYTIC PEPTIDE USED IN THE TREATMENT OF 
MYELODYSPLASTIC SYNDROMES  
 
2.1 Purpose/Goal 
Lytic peptides are antimicrobial agents known for their cytotoxicity against cancer cells causing lysis 
of the cell membrane.  In the treatment of Myelodysplastic Syndromes (MDS)1-2, a precursor to bone 
marrow cancer, a CpG-lytic peptide conjugate was designed to specifically target TLR9 receptors expressed 
on the extracellular surface on the cell membrane of these precancer cells.  Our goal was to synthesize, on 
solid support, an unmethylated CpG oligonucleotide targeting ligand attached to a lytic peptide using 
the copper-catalyzed 3+2 cycloaddition click reaction.  In vitro experiments conducted with the MDS 
malignant spleen precancer cells of S100A9-Tg mice and that of human MDS patient bone marrow cells, 
demonstrated that the CpG-lytic peptide showed a time and dose-dependent increase in apoptosis in the 
TLR9+ cells without affecting TLR9-nontransfected cells. 
2.2 Introduction 
Myelodysplastic Syndromes (MDS), also known as “bone marrow failure disorder”, are a group of diverse 
bone marrow and blood diseases in which the immature stem cells are damaged becoming mutated, 
irregularly shaped and sized1.  These abnormal cells have a short life span where they may become 
destroyed by the body resulting in cytopenia – low blood count, which may be accompanied by the loss of 
the body’s ability to fight infections and control bleeding.  In normal healthy bone marrow, immature blood 
cells develop into mature, fully functional red blood cells, white blood cells, and platelets. The effects from 
failure to produce healthy mature cells are a gradual process that reduces quality of life, but is not usually 
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a terminal disease.  However, 30% of patients diagnosed with this type of bone marrow failure syndrome 
will progress to an aggressive type of cancer called acute myeloid leukemia (AML); therefore, novel 
therapeutics that will specifically target MDS precancer cells and result in triggered cell death could help 
prevent AML.  Studies have shown that high concentrations of a lytic peptide aggregating about the cell 
surface can disrupt cancer cell membranes resulting in necrotic cell death.  Lytic peptides are 
characterized by their length, usually fewer than 27 amino acids, and their lysine-rich sequence.  In 
efforts to concentrate lytic peptides within the cell membrane of MDS cells, we designed a CpG 
Oligodeoxynucleotide-lytic peptide conjugate to target the lytic peptide to MDS cells that have an 
affinity for Toll-Like Receptor 9 (TLR9).   
In spite of an incomplete understanding of the direct cause of MDS, over the past few years 
scientists have been able to identify the risk factors and identify the causes for changes in DNA of bone 
marrow cells.  This DNA mutation causes the genes in oncogenes – genes that promote cell division – to 
be turned on, or to turn off the tumor suppressor genes that slow down cell division or even cause 
appropriate timed-cell death.  During cell division, any imperfection in the copying of DNA is corrected by 
repair enzymes or the cell would self-destruct.  However, due to rapid cell growth, these errors may continue 
and contain these altered chromosomes.  In the prognosis of MDS patients, translocation – attachment of 
one chromosome to another, deletion – part or whole of the chromosome being lost, and duplication – extra 
copy of part or all the chromosome are all chromosome abnormalities.  Prior treatment with chemotherapy 
and radiation therapy increases DNA mutations.  Other causes linked to MDS are genetic syndromes caused 
by inherited mutated genes, chemicals found in tobacco smoke, environmental exposure, as in high dose 
radiation exposure, age and sex – as MDS is more common in men.       
 Toll-Like Receptors (TLRs) are type I transmembrane proteins that play an important role the 
innate immune response against foreign microorganisms.  These receptors are pattern recognition receptors 
known to be overexpressed by epithelial tumor cells during cancer progression.  Among these TLRs, TLR9 
exhibited a significant correlation in bone marrow cells from patients with MDS and interestingly showed 
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a down-regulation at the time of transformation to AML in these patients.  TLR9 is essential for the 
recognition of unmethylated CpG DNA bacteria.  In mammals, newly synthesized oligonucleotide (ODN) 
containing the cytosine-phosphate-guanine dinucleotide motif are methylated and this DNA methylation is 
an epigenetic signature that controls gene transcription and therefore unmethylated CpG is a danger signal 
recognized by the innate immune system. The specific sequences and structural requirements of the 
oligodeoxynucleotide are unknown, however, docking experiments showed the TLR9-CpG ODN 
interaction sites were located close to the central region of the horseshoe-shaped irregular solenoid 
structure.  The computed models also elucidated that there were 25 amino acid residues in the ligand-
binding region involved in the protein-nucleic acid interface.  This was based on the size of the CpG ODN 
which occupies more than 40% of the total interface area.  Among the 25 residues of the receptor, Tyr224, 
Val248, Val290, Val312, Asp314, Arg337, Lys338, Asn340, Val364, Ala365, Lys367, Met392, and Arg397 were in direct 
contact with the CpG ODN ligand showing hydrogen bonding and hydrophobic interactions showing to be 
important for ligand recognition.7 
2.3 Experimental Procedures 
 2.3.1 Materials and Methods 
 All reagents were ACS grade obtained from commercial sources from Sigma-Aldrich, Chem-
Impex International, Fischer Scientific or Alfa Aesar.  Fmoc-protected amino acids and the coupling agents 
were obtained from Gyros Protein Technologies.  TentaGel® HL OH and Rink Amide AM resins were 
purchased from Rapp Polymere and Chem-Impex respectively.  Lytic Peptide and CpG Oligonucleotide 
were synthesized manually on solid support and phosphoramidite monomers were activated in solution 
phase and purified using Flash Chromatography.  Solvents used for synthesis were obtained from Aldrich 
of the highest purity.  Thin Layer Chromatography (TLC) was performed on glass plates, purchased from 
Merck Millipore, coated with 2.0 mm thickness of PLC silica gel 60Å.    Coupling efficiencies were 
measured using Agilent Cary 60 UV spectrometer.  All 1H and 13C NMR 1D experiments were carried out 
using Varian INOVA 400 MHz spectrometer in CDCl3 unless stated differently, and chemical shifts 
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measured in ppm (δ) relative to internal standard tetramethylsilane (TMS).  Lytic peptide and CpG-lytic 
peptide conjugate were purified on Dionex Summit HPLC Systems.   A C18 AAPPTEC spirit column (25 x 
2.12 cm, 5 μM particle size) with eluents: A = 0.1% HCO2H in H2O, B = 0.1% HCO2H in H3CCN. The 
purifications were carried out using a gradient of 2-60% Buffer B over 37 min with a flow rate 20 
mL/minute using 222 nm.  The desired peaks were collected and lyophilized for the peptide and ODN. 
Mass spectra were obtained for the peptide and ODN using both LC/MS and MALDI-TOF MS.  Each 
sample (~10-100uM) was dissolved in HPLC grade methanol in a 2-mL mass spectroscopy vial and 
submitted to the Triple quadrupole (TSQ Quantum Ultra, Thermo) LC/MS.  The samples of the 
phosphoramidite monomers were ran in positive ion-mode adding 0.1% formic acid to the analyte solution 
to enhance protonation and increase sensitivity and negative mode for the oligonucleotide fragments.  
MALDI-TOF mass spectroscopy, Applied Biosystems 4700 Proteomics Analyzer 347000087, was used to 
characterize the oligonucleotide and lytic peptide.  A solution of the HPA matrix, used for the ODN and 
CHCA, used for the peptide, (50 mg/mL) in 1:1 v/v deionized water/ ACN and mixed with a solution of 
acetylcholine (AHC) (10:1, v/v) and homogenized using a sonicator. The analyte samples were cleaved off 
resin and concentrated and dissolved in 100 µL of deionized water and mixed with the matrix, spotted on 
the plate and allowed to crystallize at room temperature. 
Table 2.1. List of chemicals used in the synthesis of the CpG-lytic peptide  
Name of Chemical Molecular Structure 
5'-O-(4,4'-dimethoxytrityl)-N6-benzoyl-2'-deoxyadenosine 
 
5'-O-(4,4'-dimethoxytrityl)-N4-benzoyl-2'-deoxycytidine 
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5'-O-(4,4'-dimethoxytrityl)thymidine 
 
5'-O-(4,4'-dimethoxytrityl)-N2-isobutyryl-2'-
deoxyguanosine 
 
3'-Azido-3'-deoxythymidine 
 
2-cyanoethyl N,N-diisopropylchlorophosphoramidite 
(CIN2OP) 
 
Fmoc-L-glutamic acid g-benzyl ester 
 
4-(chloromethyl)benzoic acid 
 
5-Methyl-1H-tetrazole 
 
 
Pyridine 
 
N,N-Diisopropylethylamine (DIEA) 
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2-(6-Chloro-1-H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate (HCTU) 
 
Acetic Anhydride (CH3CO)2O 
 
N-methylimidazole  
 
Tetrahydrofuran (THF) 
  
4-Dimethylaminopyridine (DMAP) 
 
 
18-Crown-6 
 
Trifluoroacetic acid (TFA) 
 
Trichloroacetic acid (TCA) 
 
Triisopropylsilane (TIS) 
 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) 
 
ethylenediaminetetraacetic acid (EDTA) 
 
Acetonitrile CH3CN 
Sodium Azide NaN3 
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Sodium ascorbate 
 
Copper (II) Sulfate CuSO4 
Dimethyl sulfoxide (DMSO) 
 
Dichloromethane (DCM) 
 
Methanol (MeOH)  
Ethyl acetate (EtOAc) 
 
Hexane (Hex)  
N-Methyl-2-pyrrolidone (NMP) 
 
Rink Amide AM Resin 
 
TentaGel® HL OH TentaGel-CH2-CH2-OH 
Iodine Crystals I2 
Cinnamic acid (CHCA) 
 
3-Hydroxypicolinic acid (HPA) 
 
 
 
2.3.2 Schematic Overview of CpG-lytic Peptide Synthesis 
Scheme 2.1, page26 describes the generalized scheme for the phosphorylation of the fully protected 
deoxynucleotides in solution phase.  The DMTr-protected dinucleotides were suspended in anhydrous 
acetonitrile.  The reaction mixture was homogenized upon addition of the 2-cyanoethyl N, N- 
diisopropylchlorophoramidite (CIN2OP) in the presence of an organic base to yield the activated 
phosphoramidite monomers 1a-1d.   
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Scheme 2.1. Phosphorylation of the fully protected deoxynucleotides in solution phase. 1.0 eq. Dmt-protected deoxynucleotide, 
2.5 eq. 2-cyanoethyl(N,N-diisopropylchlorophoramidite), 10 eq. DIEA in CH3CN anhydr.  
 The Tentagel resin was initially swelled in anhydrous DCM for an hour and coupled with Fmoc-L-
glutamic acid g-benzyl ester via a stable amide bond.  The glutamic acid was used to extend the oligomer 
chain in efforts to reduce steric hindrance when coupling to the solid support.  The amino group of the 
amino acid was Fmoc protected and was used to determine the coupling efficiency (substitution level).  In 
Scheme 2.2, the Benzyl group was deprotected with TFA to yield a free carboxylic acid that was coupled 
to the 3’ amino group of 3'-Amino-3'-deoxythymidine. 
   
Scheme 2.2. Coupling of Fmoc-L-glutamic acid γ-tert-butyl ester onto the Tentagel resin.  (a) 1.0 eq. Fmoc-L-glutamic acid g-
benzyl ester, 4.0 eq. DIEA, 4.0 eq. HCTU, 4.0 eq. DMAP in NMP r.t 
3'-Amino-3'-deoxythymidine was not available commercially therefore 3'-Azido-3'-deoxythymidine was 
reduced in the presence of Pd catalyst and hydrogen gas as outlined in Scheme 2.3.   
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Scheme 2.3. Reduction of Azide group of 3'-Azido-3'-deoxythymidine (a) 1.0 eq. 3'-Azido-3'-deoxythymidine, 10 % cat. Pd on 
carbon., H2 (g) in MeOH, r.t 
This provided an anchor to the solid support, that was shown to be stable under acidic conditions during 
the removal of the DMTr group, as outlined in Scheme 2.4.   
 
Scheme 2.4. TFA deprotection of t-butyl protecting group and 3'-Amino-3'-deoxythymidine coupling.  (a) 1.0 eq. SM, TFA. (b) 
1.0 eq. carboxylic acid SM, 4.0 eq. Thy-NH2, 8.0 eq. DIEA, 4.0 eq. HCTU in NMP r.t 
The general strategy used to synthesize the oligodeoxynucleotide was outlined in Scheme 2.5.  The first 
DMTr-protected thymine was activated and coupled to the resin in the presents of a weak acid catalyst, 
methyl tetrazole.  The resin is then washed multiple times with NMP and DCM.  The resin was the capped 
with acetic anhydride to protect any free 3`-OH groups.  The phosphorous of the phosphate backbone 
formed has an oxidation state of +3 and was oxidized to +5 with a catalytic I2 in 50% pyridine: water.  A 
second capping step was employed to remove any excess water molecules.  The DMTr group was then 
deprotected in 2% TCA in DCM to free the 3`-OH group to couple to the next deoxynucleotide monomer.   
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Scheme 2.5. Phosphoramidite method for oligodeoxynucleotide synthesis.   (a) 1.0 eq. SM, 2% trichloroacetic acid in DCM. (b) 
activation and coupling: 1.0 eq. Resin SM, 4.0 eq. DMT-phosphitylated nucleotide, 10 mol% methyl tetrazole in anhydr. 
acetonitrile. (c) Capping: Resin, acetic anhydride, N-methylimidazole in anhydr. THF: pyridine (10:1) (d) Oxidation: cat. I2 in 
water: pyridine (1:1) 
After the synthesis of the Oligomer, the Fmoc group was removed to free the amino group which 
was coupled to 4-(azidomethyl) benzoic acid as shown in Scheme 2.6.  The azido group undergoes the click 
reaction with an alkyne via a 1,2,3 cycloaddition.      
 
Scheme 2.6. Fmoc deprotection and 4-(azidomethyl) benzoic acid coupling.  4.0 eq. 4-(azidomethyl) benzoic acid, 4.0 eq. DIEA, 
4.0 eq. HOBT, cat. DMAP in NMP 
The lytic peptide was synthesized in a second peptide vessel on Rink Amide resin.  The primary structure 
contained numerous lysine residues that contributed to the overall polar characteristics of the lytic peptide.  
The resin was swelled in NMP for 2 hours and the Fmoc protecting group was removed using DMU and 
piperidine.  Each amino acid residue was coupled to the resin and washed in between coupling.  As the 
synthesis progressed, an aliquot of the resin as dried and the Fmoc group was cleaved to determine the 
coupling efficiency.    
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4a 
 
        Scheme 2.7. Solid-phase synthesis of lytic peptide. (a) Coupling. 1.0 eq. Rink Amide AM resin (200-400 mesh), 4.0 eq. 
protected amino acid monomer, 4.0 eq. HCTU, 6.0 eq. DIEA in NMP. (b) Deprotection. 20% piperidine, 2% DBU in NMP. 
 In a secondary peptide vessel, the lysis peptide was synthesized on solid support (Rink Amide AM 
Resin).  Periodically an aliquot of the resin was dried, weighed and the Fmoc protecting group on the 
terminal amino acid was cleaved to determine the coupling efficiency.  It was necessary to couple the amino 
acid monomers to ensure sufficient uploading on to the resin.  The overall primary structure of the peptide 
is shown in Scheme 2.7.   
 
 Scheme 2.8. 5-Hexyonic acid coupling to lytic peptide on solid support. 1.0 eq. Resin-NH2, 4.0 eq. 5-hexyonic acid, 4.0 
eq. HCTU, 6.0 eq. DIEA in NMP. 
The Fmoc group was removed from the terminal amino acid and 5-hexyonic acid was coupled to form a 
stable amide bond as shown in Scheme 2.8.  The alkyne function group was extended from the peptide in 
efforts to minimize steric hindrance during the click reaction with the azide group on the oligonucleotide.  
The peptide was then cleaved of the resin, extracted and purified using preparatory HPLC and characterized 
by MALDI.   
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Scheme 2.9. Tandem copper catalyzed click reaction between CpG ODN and lytic peptide. 1.0 eq. resin, 4.0 eq. acetylated peptide, 
3.0 eq. sodium ascorbate, 1.0 eq. CuSO4, 8.0 eq. DIEA, H20 
 The CpG -lytic peptide conjugate was concluded on the Tentagel resin in aqueous conditions.  In 
the presence of the Cu2+ catalysis, the azide-alkyne cycloaddition selectively yielding a 1,2,3 triazole as 
outlined in Scheme 2.9.  The conjugate was then cleaved off resin removing all protecting groups off the 
oligonucleotide and purified by HPLC.  In vitro studies were then carried out on MDS malignant spleen 
precancer cells of S100A9-Tg and bone marrow cells of human patients, further discussed in section 2.4.4. 
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2.3.3 Solution Phase Synthesis of Oligonucleotide Monomers  
 
1a 
5'-O-(4,4'-Dimethoxytrityl)-N6-bz-2'-deoxyadenosine-4-[2-Cyanoethyl]N,N-
diisopropylphosphoramidite. To a suspended solution of 5'-O-(4,4'-Dimethoxytrityl)-N6-benzoyl-2'-
deoxyadenosine (1.00 g, 1.52 mmol) in freshly distilled anhydrous acetonitrile (10 mL), DIEA (2.51 mL, 
15.2 mmol) was added dropwise at room temperature, r.t. under argon. To the mixture, CIN2OP (0.85 mL, 
3.80 mmol) was added and the reaction was monitored by TLC until all the starting material was consumed.  
The reaction mixture was then concentrated, taken up in ethyl acetate (30 mL) and washed with brine (10 
mL, x3).  The organic layers were extracted, dried over Na2SO4 and concentrated leaving an oil which was 
furthered purified by column chromatography using EtOAc/Hex (50:50, v/v) to elute a white solid,1a (0.868 
g) in 66.7% yield.         
 
1b 
5'-O-(4,4'-Dimethoxytrityl)-N2-iBul-2'-deoxyguanosine-4-[2-Cyanoethyl]N,N-
diisopropylphosphoramidite. To a suspended solution of 5'-O-(4,4'-Dimethoxytrityl)-N2-iBul-2'-
deoxyguanosine (2.00 g, 3.13 mmol) in a mixture of freshly distilled anhydrous acetonitrile: 
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dichloromethane (10 mL:10mL), DIEA (5.17 mL, 31.3 mmol) was added dropwise at room temperature, 
r.t. under argon.  To the mixture, CIN2OP (1.75 mL, 7.82 mmol) was added and the reaction was warmed 
gently and monitored by TLC until all the starting material was consumed.    The reaction mixture was then 
concentrated and taken up in EtOAc (60 mL) and washed with brine (15 mL, x3).  The organic layers were 
extracted, dried over Na2SO4 and concentrated leaving an oil which was furthered purified by column 
chromatography using EtOAc/Hex (80:20, v/v) to elute a white solid, 1b (1.82 g) in 69.5% yield.  LCMS 
m/z (ESI) for C44H54N7O8P mw. 839.38, Fragment Ions: 218.9, 303.1, 436.9, 757.2. 
1H NMR (400 MHz, 
CDCl3) 8.72, (bs, 1H), 7.75 (s, 1H), 7.15- 7.30 (m, 14H), 6.20 (t, 1H), 4.65 (bs, 1H), 4.20 (m, 1H), 3.78 (s, 
8H), 3.5 (m, 2H), 3.35-3.30 (dd, 2H), 3.25-3.20 (dd, 2H), 2.75 (m, 3H), 2.40 (m, 1H), 2.25 (m, 1H), 1.25 
(d, 12H), 1.15 (d, 4H), 0.95 (d, 4H).    
 
1c 
5'-O-(4,4'-dimethoxytrityl)thymidine-4-[2-Cyanoethyl]N,N-diisopropylphosphoramidite. To a 
suspended solution of 5'-O-(4,4'-dimethoxytrityl)thymidine (2.00 g, 3.67 mmol) in freshly distilled  
anhydrous acetonitrile (20 mL), DIEA (6.07 mL, 36.7 mmol) was added dropwise at room temperature, r.t. 
under argon.  To the mixture, CIN2OP (2.05 mL, 9.18 mmol) was added and the reaction was monitored by 
TLC until all the starting material was consumed.  The reaction mixture was then concentrated and taken 
up in ethyl acetate (60 mL) and washed with brine (15 mL, x3).  The organic layers were extracted, dried 
over Na2SO4 and concentrated leaving an oil that was further purified by column chromatography using 
EtOAc/Hex (50:50, v/v) to elute a white solid, 1c (2.13 g) in 76.5% yield.  1H NMR (400 MHz, CDCl3) 
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8.26, (bs, 1H), 7.60 (d, 1H), 7.25 (m, 13H), 6.35 (q, 1H), 4.65 (m, 1H), 3.78 (s, 6H), 3.65-3.45 (m, 5H), 
3.30 (m, 1H), 2.60 (t, 1H), 2.40 (t, 1H), 2.30 (m, 1H), 1.60 (s, 3H), 1.25 (d, 2H), 1.15 (d, 12H).     
 
1d 
5'-O-(4,4'-dimethoxytrityl)-N4-benzoyl-2'-deoxycytidine-4-[2-Cyanoethyl]N,N-
diisopropylphosphoramidite. To a suspended solution of 5'-O-(4,4'-dimethoxytrityl)thymidine (2.00 g, 
3.16 mmol) in freshly distilled anhydrous DCM (20 mL), DIEA (1.67 mL, 10.1 mmol), CIN2OP (1.76 mL, 
7.89 mmol) and 1-methylimidazole (0.199 mL, 2.52 mmol) was added at 0oC, under argon. The reaction 
was monitored by TLC until all the starting material was consumed.  The reaction mixture was cooled to 
0oC and quenched with methanol (1.25 mL) and stirred for five (5) minutes.  The mixture was then 
concentrated and taken up in ethyl acetate (60 mL) and washed with brine (15 mL, x3).  The organic layers 
were extracted, dried over Na2SO4 and concentrated leaving an oil which was furthered purified by column 
chromatography using EtOAc/Hex (60:40, v/v) to elute a white solid, 1d (1.84 g) in 70.0% yield. LCMS 
m/z (ESI) for C46H52N5O8P mw. 833.36 Fragment ion 750.7. 
1H NMR (400 MHz, CDCl3) 8.6 (bs, 1H), 7.85 
(d, 3H), 7.57 (t, 1H), 7.48 (t, 3H), 7.30-7.20 (m, 10H), 6.25 (q, 1H), 4.60 (m, 1H), 3.80 (s, 9H), 3.65-3.50 
(m,5H), 2.75 ((m, 1H), 2.60 (t, 1H), 2.45 (t, 1H), 2.3 (m, 1H), 1.25 (m, 2H), 1.15 (m, 14H).    
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2a 
3'-Amino-3'-deoxythymidine.  3'-Azido-3'-deoxythymidine (2.0 g, 7.48 mmol) was dissolved in methanol 
(20 mL) and a catalytic amount of 10 wt % Pd/C was added.  The starting material was shaken on a 
hydrogenator with a positive pressure of hydrogen gas for four (4) hours.  The product was filter over Celite 
and the solvent was removed.  The crude product was triturated with ethyl acetate (10 mL) to yield a white 
solid, 2a (1.67 g,) in 92.4% yield.  LCMS m/z (ESI) for C10H15N3O4 mw. 241.11 [M+H] 241.9. 
1H NMR 
(400 MHz, CDCl3), 7.75 (s, 1H), 6.05 (t, 1H), 3.65-3.3.55 (dd, 2H), 3.50 (m, 1H), 3.35 (q, 1H), 2.45 (s, 
2H), 2.05 (m, 1H), 1.95 (m, 1H), 1.75 (s, 3H).     
   2.3.4 Oligonucleotide Synthesis and Stabilization 
 
2b 
Fmoc-L-glutamic acid g-benzyl ester Coupling to TentaGel® HL OH. Tentagel resin (0.150 g, 0.43 
mmol/g) was swelled in anhydrous dichloromethane (3 mL) for an hour.  In a reaction vessel, Fmoc-L-
glutamic acid g-benzyl ester (0.109 g, 0.256 mmol), DIEA (0.0423 mL, 0.256 mmol), HCTU (0.106 g, 
0.256 mmol) and DMAP (0.03 g, 0.256 mmol) were dissolved at r.t. in NMP (1 mL) under argon.  The 
reaction mixture was added to the resin in the peptide vessel and coupled for three (3) hours.  The resin was 
washed with NMP (3 mL, x3) and dichloromethane (3 mL, x3).  The procedure was repeated.  An aliquot 
of the resin (7.1 mg) was dried under high vacuum for 24 hrs.   2 mL of a 2% DBU (0.08 mL) in NMP (4 
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mL) was added to the resin and stirred for 15 minutes and then diluted with acetonitrile (10 mL).  The 
diluted solution (2 mL) was further diluted to 25 mL with acetonitrile.  Using Agilent Cary 60 UV 
spectrophotometer, at wavelength 301 nm, the solution was used to determine the concentration of Fmoc 
(0.32 mmol/g) in 74.4% coupling efficiency.    
 
2c 
3'-Amino-3'-deoxythymidine coupling.  The resin (0.150 g, 0.32 mmol/g) was swelled in 
dichloromethane (1 hr., 3 mL).  Trifluoracetic acid (2mL, x2) was added to the peptide vessel to cleave the 
t-butyl group.   The resin was washed with NMP (3 mL, x3) and dichloromethane (3 mL, x3).  3'-Amino-
3'-deoxythymidine (0.0462 g, 0.192 mmol), DIEA (0.0600 mL, 3.84 mmol) and HCTU (0.079 g, 0.192 
mmol) were dissolved in NMP (1 mL) and coupled to the resin (2 hr. x2).  The resin was washed with 
NMP (3 mL, x3) and dichloromethane (3 mL, x3).  An aliquot was cleaved from the resin to confirm 
coupling.  LCMS m/z (ESI) for C30H32N4O7 mw. 592.22. Fragment ions 124.0, 371.0 
 
3a 
Detritylation.  The resin (0.150 g, 0.32 mmol/g) was swelled in dichloromethane (1 hr., 3 mL).   2% 
trichloroacetic acid in dichloromethane was added to the resin (5 mL, x2) to remove the DMTr protecting 
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group.  The resin was washed with NMP (3 mL, x3) and dichloromethane (3 mL, x3). 
Activation and Coupling.  Each phosphoramidite monomer, compound 1a-1d (0.188 mmol), methyl 
tetrazole (0.01 g, 0.119 mmol) was dissolved in acetonitrile (0.5 mL) and coupled to the resin (1 hr. x2).  
The resin was washed with NMP (3 mL, x3) and dichloromethane (3 mL, x3).  
Capping.  Acetic anhydride (0.5 mL) and N-methylimidazole (0.4 mL) were added to THF (10 mL) and 
pyridine (1 mL) and added to the resin (5 mL, x2).   The resin was washed with NMP (3 mL, x3) and 
dichloromethane (3 mL, x3). 
Oxidation.  Pyridine (1 mL), iodine solution (1 mL) was added to the resin until the brown solution turned 
colorless.  The resin was washed with NMP (3 mL, x3) and dichloromethane (3 mL, x3).  The Capping step 
was repeated.    
 
3b 
4-(azidomethyl)benzoic acid.  4-(chloromethyl) benzoic acid (0.500 g, 2.94 mmol) was dissolved in 
dimethyl sulfoxide (5 mL) and stirred for 5 minutes.   In another reaction vessel, sodium azide (0.382 g, 
5.88 mmol) and 18-Crown-6 were stirred vigorously in a dimethyl sulfoxide: water mixture (5 mL: 1 mL) 
until all the of the sodium azide was dissolved and then added to the starting material and stirred for 24 hr. 
at r.t.  The reaction was then diluted with ethyl acetate (20 mL) and washed with 0.1 N hydrochloric acid 
(10 mL, x2) and then brine (10 mL, x2).  The organic layer was extracted, dried over Na2SO4 and 
concentrated leaving a white solid, 3b (0.523 g) in 86.8% yield.  LCMS m/z (ESI) for C8H7N3O2 mw. 
177.05 [M+H] 178.0.  13C NMR (101 MHz, CDCl3) 167.8, 141.5, 131.7, 131.5, 129.0, 51.9. 
 
37 
 
 
3c 
4-(azidomethyl)benzoic acid coupling to resin.   The resin (0.150 g, 0.32 mmol/g) was swelled in 
dichloromethane (1 hr., 3 mL).   20% piperidine, 2 % DBU (3 mL, x2) was added to the resin to deprotect 
the Fmoc protecting group.  The resin was washed with NMP (3 mL, x3) and dichloromethane (3 mL, x3).  
4-(azidomethyl) benzoic acid (0.0340 g, 0.192 mmol), DIEA (0.0334 mL, 0.192 mmol), HCTU (0.0794 g, 
0.192 mmol) and DMAP (0.0234 g, 0.192 mmol) were dissolved in NMP (1 mL) and coupled to the resin 
(3 hr. x2).  The resin was washed with NMP (3 mL, x3) and DCM (3 mL, x3). 
2.3.5 Peptide Synthesis and Purification Methods 
 
Peptide.  Rink Amide AM resin (1.50 g, 0.71 mmol/g) was swelled in NMP (3 mL) for 2 hours.  20% 
piperidine, 2 % DBU in NMP (3 mL, x2) was added to the resin to deprotect the Fmoc protecting group.  
The resin was washed with NMP (3 mL, x3) and dichloromethane (3 mL, x3).   An aliquot of the resin 
(9.80 mg) was dried under high vacuum for 24 hrs.   2 mL of a 2% DBU (0.08 mL) in NMP (4 mL) was 
added to the resin and stirred for 15 minutes and then diluted with acetonitrile (10 mL).  The diluted solution 
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(2 mL) was further diluted to 25 mL with acetonitrile.  Using Agilent Cary 60 UV spectrophotometer, at 
wavelength 301 nm, the solution was used to determine the concentration of Fmoc (0.597 mmol/g) in 84.5% 
coupling efficiency.   
Capping.  The unreacted amines were capped with a capping solution by combining acetic anhydride and 
pyridine (30:20, v/v) and added to the resin for 20 min.  The resin was then washed with NMP (30 mL, x3) 
and DCM (30 mL, x3). 
Coupling and deprotection. Each amino acid monomer (3.59 mmol), DIEA (0.935 mL, 5.37 mmol) and 
2-(6-Chloro-1-H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (1.48 g, 3.59 
mmol) were dissolved in NMP (10 mL) and coupled to the resin (90 minutes.).  The amino acids were 
coupled in the following sequence order: Fmoc-Lys(Boc)-OH, Fmoc-Ala-OH, Fmoc-Phe-OH, Fmoc-
Lys(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ala-OH, Fmoc-Phe-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ala-OH, 
Fmoc-Phe-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ala-OH, Fmoc-Phe-OH, Fmoc-
Lys(Boc)-OH, Fmoc-Ala-OH, Fmoc-Phe-OH, Fmoc-Lys(Boc)-OH.  The resin was washed with NMP (30 
mL, x3) and DCM (30 mL, x3). After each amino acid was coupled to the resin (1.50g, 0.597 mmol/g), the 
Fmoc protecting group was removed using 20% piperidine, 2 % DBU in NMP (30 mL, x2).   
 
4a 
Coupling of   5-hexynoic acid.  20% piperidine, 2 % DBU in NMP (20 mL, x2) was added to the resin to 
deprotect the Fmoc protecting group.   The resin was washed with NMP (30 mL, x3) and dichloromethane 
(30 mL, x3).  5- hexynoic acid (0.397 mL, 3.60 mmol), DIEA (0.941 mL, 5.40 mmol), 2-(6-Chloro-1-H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (1.49 g, 3.60 mmol) and a catalytic 
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amount of 4-dimethylaminopyridine were dissolved in NMP (10 mL) was coupled to the resin (1.50 g, 0.60 
mmol/g).  The resin was washed with NMP (30 mL, x3) and dichloromethane (30 mL, x3).  
 
 
4b 
Cleavage of the Peptide from the resin.  85% trifluoracetic acid, 5% water, 5% triisopropylsilane, 5% 
dichloromethane (30 mL) was added to the resin and bubbled for 30 minutes.  The solution was collected 
in a flask and the resin was rinsed with trifluoracetic acid and drained into the flask.  The solution mixture 
was concentrated, and cold ether was added to the crude peptide to precipitate the peptide.  The ether was 
decanted, and the peptide was washed with cold ether.  The peptide was then dissolved in water, frozen and 
placed on the lyophilizer for 48 h leaving a white solid, (0.362 g) in 18.1 %.  MALDI-MS m/z (TOF) for 
C114H175N27O19 mw. 2226.36 [M+H] 2226.7603 
2.3.6 CpG-Lytic Peptide cycloaddition 
 
4c 
CpG-lytic Peptide.  The resin (0.127 g, 0.32 mmol/g) was swelled in NMP (3 mL) for 1 h. then rinsed with 
NMP: water mixture (1.5 mL: 1.5 mL).   The peptide (0.362 g, 0.163 mmol), copper (II) sulfate (0.00583 
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g, 0.0406 mmol), sodium ascorbate (0.0242 g, 0.121 mmol) and DIEA (0.0566 mL, 0.325 mmol) were 
dissolved in NMP (1 mL) and coupled to the resin (24 hr).  The resin was washed with NMP (3 mL, x3), 
dichloromethane (3 mL, x3), acetonitrile (3mL, x3), an EDTA solution (3 mL, 0.05 M) and an acetonitrile: 
water mixture (1.5 mL:1.5 mL, x3).    
Deprotection of DMTr: 2% trichloroacetic acid in dichloromethane was added to the resin (5 mL, x2) to 
remove the DMTr protecting group.  The resin was washed with NMP (3 mL, x3) and dichloromethane (3 
mL, x3).  Cleavage of CpG-lytic peptide from resin: 2% DBU (0.16 mL) in NMP (8 mL) was added to 
cleave the cyanoethyl protecting groups and then a mixture of 33% ammonia and 40% triethylamine was 
added to remove the nucleobases protecting groups and cleave the CpG-lytic peptide from the resin.  
2.4 Results and Discussion 
  2.4.1 Synthesis of Oligonucleotide monomers 
 In the synthesis of the CpG oligonucleotide, the exocyclic primary amino groups on the 
heterocyclic bases of the deoxynucleotide monomers guanine, cytosine, and adenosine were protected with 
protecting groups that were stable in the acidic conditions during detritylation.  They were removed in the 
final deprotection of the CpG-lytic peptide by prolonged treatment with a mixture of 33% ammonia and 
40% triethylamine instead of concentrated ammonium hydroxide at 55oC for one hour to prevent 
degradation of the conjugate.  The phosphate groups along the backbone of the growing ODN were 
protected throughout the synthesis and were deprotected with 2% DBU/NMP (1:50, v/v) prior to the final 
cleavage as shown in Figure 2.1. 
 
Figure 2.1: The mechanism of the cyanoethyl phosphodiester deprotection of the cyanoethyl protecting group in the presence of 
ammonia. 
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The milder basic mixture used for the final cleavage was preferred to prevent the side reaction of 
acrylonitrile with thymidine as a by-product of the phosphodiester deprotection that generally occurs 
under strong basic conditions of concentrated ammonia as shown in Figure 2.  The acrylonitrile acts a 
Michael acceptor and under alkaline pH the N(3) proton for thymine (pKa = 9.5) is removed.  Mass 
spectroscopy studies of four different ODN fragment sequences confirmed that this Micheal addition did 
not occur. 
 
 
Figure 2.2: The mechanism of the formation of cyanoethyl adducts of thymidine with acrylonitrile under strong basic conditions 
The fully protected deoxynucleotide monomers, dTDMTr, dCDMTr/Bz, dADMTr/Bz and dGDMTr/iBu were 
commercially available.  However, it was necessary to activate the 3`-position hydroxyl group using 
ClN2OP in the presence of a non-nucleophilic base in solution phase and these intermediates were purified 
using flash chromatography to give the phosphoramidite monomers.  The monomers were made on a 2.0g 
scale and stored under inert conditions at 0oC for up to 3 months. Table 2.2, page 41, provides a summary 
of reaction times and yields for the deoxynucleotide protected monomers.   
During the solution-phase synthesis, there were a few challenges faced.  The reaction with 
dGDMTr/iBu required an excess of CIN2OP was required and the reaction was repeated until all starting 
material was consumed.  CIN2OP reagent is costly and is sensitive to moisture undergoing hydrolysis at the 
phosphorus atom and becoming unreactive. 
In addition, because the phosphorus is tetrahedral and therefore a chiral center, the phosphoramidite 
monomer produced gives rise to the formation of a mixture of two diastereomers, shown in Figure 2.3, that 
were impossible to separate on column.   
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Figure 2.3:  Phosphoramidite diastereomers structures of the two diastereomers of the phosphoramidite monomer 
Table 2.2: Cyanoethylation of the fully protected deoxynucleotide monomers in solution phase synthesis 
       ___________________________________________________________ 
  Entry  Base (R)  Time (h)           Yield (%) 
  ___________________________________________________________   
1a     5   66.7 
1b    24   69.5  
1c    4   70.0 
1d    2   76.5 
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The germinal protons of the cyanoethyl group are diastereotopic protons and in some cases showed up as 
four separate peaks as triplets or an overlapping multiplet on 1H NMR becoming challenging to characterize 
the phosphoramidite monomers.  There were no molecular ion peaks seen on LC/MS only fragment ions 
with the diisoproylamine removed from the parent molecule as shown in Appendix A.   
 During the synthesis of the 21-monomer ODN, we were concerned with the depurination of the A 
and G heterocyclic bases under acidic conditions required for the repeated DMTr group removal during 
chain elongation.  The stability of the glycosylic bonds of dABz and dGDmf was evaluated by treating the 
nucleosides, separately, in solution phase with 2% TCA/DCM for 24 h at r.t.  The deoxynucleotides were 
extracted with ethyl acetate, washed with a minimal volume of brine, dried Na2SO4 and concentrated.  The 
extracted compounds showed one spot on TLC, stained with iodine, and had the same calculated Rf value 
as the starting material.  The LC/MS and 13CNMR spectra confirmed the presence of the bases as shown in 
Table 2.3.   The fragment ion peak at 336.3 in the LC/MS spectra for dABz suggest the removal of H2O 
molecule in the positive ion mode with the purine base still intact.  No 13C NMR was recorded at that time.    
Both LC/MS and 13C NMR spectra confirmed the presence of the base in dGDmf as shown in Table 2.3. 
Table 2.3: Isolated sequences and coupling efficiencies of ODNs 
Base                    LC/MS [M+H]                                             13C NMR 
                      Calcd.               Found                   
 
dABz 355.13 336.3  
    
dGDmf   322.14                 323.1 158.2, 157.4, 157.2, 150.0, 136.5, 120.0, 88.1, 83.6, 
                      71.8, 62.1, 41.8, 35.8  
 
 
 
             2.4.2 MALDI and LC/MS Studies for Oligonucleotide Characterization 
In the elongation of the ODN, the coupling efficiency was monitored during the removal of the 
DMTr group.  We thought that by treating a known mass of the resin with 2% TCA/DCM we can 
quantitatively measure the concentration of DMTr carbocation in solution which would correlate to the 
concentration of DMTr protected monomer coupled to the resin.  A standard curve was generated from 
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measuring the absorbance at wavelength 504 nm of known concentrations of DMTr in DCM.  4,4-
Dimethoxy trityl chloride was added to 2% TCA in DCM and further diluted to known concentrations.    
Table 2.4: Concentration of DMTr carbocation in DCM vs absorbance at 504 nm  
[DMTr+] mM Absorbance at 504 nm 
 
4.580 1.408 
3.425 1.239 
2.576 1.100 
1.932 0.855 
1.449            9.654                      
0.000 0.000 
A graph of the absorbance vs the concentration of the standard solutions generates a plot that can correlate 
with Beer-Lambert’s law (A = Ɛ c d) where A is the absorbance, d is the path length of light through the 
sample (a standard Genisys 20 tube is 1 cm) and Ɛ is the molar absorptivity – how strong a specific substance 
absorbs light.   
Table 2.5. Coupling efficiencies of phosphoramidite monomers of the CpG oligomer.  
ODN Sequence            Yield (%) 
Glu-d[TT] 57.5 
Glu-d[TTC] 48.8 
Glu-d[TTCG] 46.9 
Glu-d[TTCGT] 46.5 
Glu-d[TTCGTA] 45.8 
Glu-d[TTCGTAGTCCTT] 40.7 
Glu-d[TTCGTAGTCCTTGCAGTACCT] 39.4 
 
y = 356.68x
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Graph 2.1: Standard curve of concentration of DMTr versus absorbance 
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The y-intercept was set at 0 by “blanking” the spectrophotometer with DCM.  The absorptivity was 
calculated to be 356.68 and therefore the concentration of DMTr in solution after each coupling was 
measured from its absorbance.  The absorbance of selected ODN fragment sequences was measured, related 
to the coupling efficiency of the phosphoramidite monomers and reported in Table 2.5, page 44.  The % 
yields were calculated from the substitution level determined after the coupling of the glutamic acid.  As 
the chain grows the coupling efficiency decreases.   
Table 2.6. Q-TOF peaks of isolated sequence Glu-d[TTC] in negative mode 
Entry     ODN Sequence         Molecular Formula                                 Q-TOF Peaks  
                                                                                                          Calcd.               Found                                
         
2 Glu-d[TTC] [C34H41N9O20P2
6-] 2NH4
++ 2K+  535.60  536.1681  
[C34H45N9O20P2
2-] NH4
+   979.26  981.2832  
 
 
Aliquots of the resin were treated with 2% DBU in NMP and 33% ammonia.  The peaks shown confirmed 
the deprotection of the 2-cyanoethyl and the base protecting groups.  The increase in oxidation state of the 
phosphorus atom from +3 to +5 was also evident in the ODN sequences which confirmed the stability of 
the oligonucleotide.   
Table 2.7. MALDI-MS peaks of isolated sequences of ODNs 
Entry     ODN Sequence            Molecular Formula                                              MALDI-TOF  
                                                                                                                         Calcd.               Found                 
         
1 Glu-d[TT]  [C40H42N6O15P
-]                877.25  877.2417  
 
2 Glu-d[TTC]  [C49H54N9O22P2
3-]2K+   1260.21            1262.7944          
              
3 Glu-d[TTCG]  [C59H66N14O28P3
3-]Na+     767.16  769.7337 
    [C59H64N14O28P3
5-]4K+   1665.18 1665.18   
5 Glu-d[TTCGTAGT] [C99H113N28O53P7
7-]3K+H+  958.80  960.8132 
 
Samples from the same aliquot of resin were characterized using LC/MS and MALDI-TOF (HPA matrix) 
summarizing the peaks found in Table 2.5.  The molecular ion peak showed negative charges within the 
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phosphate backbone and deprotonation of the thymidine bases at peak 536.1681coupled with NH4
+ and 
K+ ions.  Samples of the analyte sequences were also characterized on MALDI-TOF and LC/MS and 
summarized in Tables 2.7 and 2.8. 
Table 2.8. LC/MS peaks of isolated sequences of ODNs 
Entry     ODN Sequence          Molecular Formula                                       LC/MS 
                                                                                                            Calcd.               Found           Method 
         
1 Glu-d[TT]  [C25H37N6O14P
2+]             338.10  339.9           +ve 
 
2 Glu-d[TTC]  [C34H47N9O20P2
2-]2H+   963.25  963.1             +ve  
3 Glu-d[TTCG]  [C44H55N14O26P3
4-] 2K+    686.10  686.9  -ve 
    [C44H56N14O26P3
3-] K+    664.12  665.0 
4 Glu-d[TTCGTAG]  [C74H90N27O44P6
9-] NH4
+ 249.60  248.8  -ve 
 
              
 2.4.3 MALDI Studies for Characterization of Peptide Sequence 
 The lytic peptide is an 18-amino acid oligomer with a modified N-terminus built on the Rink Amide 
(aminomethyl) polystyrene resin, and upon cleavage yielded a C-terminal amide.  The coupling efficiency 
was monitored by the concentration of Fmoc on the N-terminus and MALDI-TOF studies of the sequences.  
During the SPPS, an aliquot of the resin was dried and weighed.  2% DBU, 20% piperidine in NMP was 
added and diluted to determine the absorbance of the Fmoc.  The coupling efficiency was calculated from 
the original substitution level.  To another aliquot the peptide was cleaved off to determine the m/z on 
MALDI-TF and LC/MS as shown in Table 2.8, page 46.  After the sequence KKFAK it became more 
challenging to detect the parent ion using LC/MS.  Due to the lysine side chains, multiple positive charges 
were observed on the peptide sequences.   
In contrast to the oligonucleotide, the peptide sequences co-crystallized with the matrix more efficiently 
and therefore were ionized and detected with more accuracy.  MALDI-TOF is commonplace for its soft 
ionization and sensitivity in characterizing biomolecules.  The use of the CHCA matrix employs a free 
carboxylic functionality essential for its performance by incorporating into the matrix crystal lattice via ion-
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pair formation with positively charged peptide functional groups.  The matrix, as a chemical ionization 
reagent, shows abundant ion signal in the positive mode by a proton transfer to the peptide sequences.  This 
sensitivity is validated with an average of 0.008922% margin of error compared to that of the LC/MS which 
showed a calculated error of 0.05908%. 
Table 2.9: MALDI-MS and LC/MS peaks of isolated sequences of the lytic peptide 
Entry     ODN Sequence                                   MALDI-TOF Mass [M+H]                  LC/MS [M+H] 
                                                                           Calcd.                    Found               Calcd.               Found 
         
6 Fmoc-AF        439.23  438.9 
 
7 Fmoc-FAK                    586.30  585.9 
8 Fmoc-KFAK        714.40  713.9 
9 Fmoc-KKFAK        842.49  841.9 
          421.75  421.6 
          281.50  281.4 
10 Fmoc-FAKKFAK   1060.60 1060.6550 
11 Fmoc-AKKFAKFAKKFAK  1735.03 1735.0841 
12 Fmoc-AKFAKKFAKFAKKFAK  2080.23 2080.5615 
4c Hex-KFAKFAKKFAKFAKKFAK 2227.36 2227.6736 
 
In contrast to the oligonucleotide, the peptide sequences co-crystallized with the matrix more efficiently 
and therefore were ionized and detected with more accuracy.  MALDI-TOF is commonplace for its soft 
ionization and sensitivity in characterizing biomolecules.  The use of the CHCA matrix employs a free 
carboxylic functionality essential for its performance by incorporating into the matrix crystal lattice via ion-
pair formation with positively charged peptide functional groups.  The matrix, as a chemical ionization 
reagent, shows abundant ion signal in the positive mode by a proton transfer to the peptide sequences.  This 
sensitivity is validated with an average of 0.008922% margin of error compared to that of the LC/MS which 
showed a calculated error of 0.05908%. 
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  2.4.4 HPLC and MALDI Studies for CpG-Lytic Peptide Conjugate 
 Reserved-Phase HPLC was used for the analysis and purification of the lytic peptide and the 
conjugate.  Due to its high resolution it separated the desired polypeptide chains peaks from any side 
products that were present as shown in Figure 2.4.  
 
Figure 2.4. HPLC spectrum of N-terminus modified lytic peptide using a gradient of 2-60% buffer B over 37 min with a flow rate 
20 mL/minute using 222 nm.  
The peak at time 19 -20 min was collected and lyophilized and showed a peak at 2227.6736 on MALDI-
TOF confirming the coupling of the hexynoic acid.   
The alkyne undergoes a Huisgen 1,3-Dipolar Cycloaddition, similar to that of a Diels-Alder 
reaction in which a dipolarophile (alkyne) reacts with a 1,3-dipolar compound (azide) that leads to the 5-
membered heterocyclic 1,2,3-triazole as described in the mechanism in Figure 2.5.  
 
Figure 2.5: Mechanism of the1,3-dipolar cycloaddition of the alkyne and azide groups to form the 1,2,3-triazole functionality. 
The resin was then washed with multiple solvents to remove all traces of the Cu(II) catalyst and purified 
using HPLC, Figure 2.6, page 48.    
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Figure 2.6: HPLC spectra of CpG-lytic peptide  
The peak at time 16.278 min was collected and the MALDI-TOF spectra, Figure 2.7, confirmed the 
presence of the lytic peptide at 2227.5317 m/z.  We hypothesized that since the lytic peptide was detected 
the click reaction was successful despite no molecular ion peak was seen for the CpG conjugate.  
 
Figure 2.7. MALDI-TOF spectra of collected HPLC peak at time 16.278 min. 
Lytic peptide 
50 
 
2.4.5 In-vitro studies 
The pathophysiology of MDS is challenging to dissect due to its complex molecular pathways and 
a lack of an adequate animal model that fully recapitulate the role of inflammation in the abnormal 
hematopoiesis.  Dr. Wei’s research group, of the Immunology Program at the Moffitt Cancer Center, 
generated S100A9 transgenic mice (S100A9Tg), with induced MSD and an overexpression of TLR9 
receptors.  In vitro studies were conducted with the MDS malignant spleen precancer cells and that of 
human MDS patient bones marrow cells to determine the time and dose-dependence of the CpG-lytic 
peptide on the apoptosis of Splenocytes.  Preliminary studies demonstrate a dose-dependent increase in 
apoptosis in transfected TLR9+ cells without affecting TLR9-nontransfected cells, demonstrating the 
feasibility of the delivery approach as shown in Figure 2.8.  
 
 
Figure 2.8: Treatment of TLR9 transfected cells with increasing doses of CpG-lytic peptide for 48 hours. 
After the 48 hours, the cell death was measured by flow cytometry.  The dotted line represents a control of 
TLR9 negative cells with 10ug/ml of the CpG-lytic peptide.  Further studies were done on TLR9+ 
Splenocytes of S100A9Tg and Wild-type (WT) with CpG control and CpG-lytic and summarized in Figure 
2.9.   In the WT, there were no significant changes in the TLR9+ Splenocytes and apoptosis % when treated 
with 2.5 µg/mL of either Control CpG or CpG lytic for 24 hours that allowed us to hypothesize that normal 
cells were not affected.  However, in comparison to that of the TG spleen cells, we saw an inverse 
proportionality of ~50%.   
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Figure 2.9.  In vitro studies of TLR9+ splenocytes and apoptosis % Wild-Type (WT) and S100A9Tg (TG) treated with 2.5 µg/mL 
of control CpG or CpG lytic peptide. 
 The time and dose-dependence studies showed within a 24 h. treatment, apoptosis occurred rapidly 
within the first 3 hours at 2.5 µg/mL.   
     
Figure 2.10. Time and dose-dependence TLR9+ studies of S100A9Tg spleen cells with CpG control and lytic peptide.  
Conclusion 
CpG-lytic peptide has proven to be a potential therapeutic in the treatment of Myelodysplastic 
Syndromes according to in vitro studies.  While there were challenges faced in the characterization methods 
of the primary structure of the oligonucleotide, beyond 8 monomers, the presence of the peptide peak 
confirmed the cycloaddition of the peptide to the ODN.  In addition to, the biological activity shown with 
spleen cells of transgenic mice confirmed the CpG fragment present in the oligonucleotide sequence that 
targeted the TLR9 receptor.  There was also a 50% increase in triggered cell death within 3 hours with 
treatment of 2.5 µg/mL of CpG-lytic peptide conjugate relative to the CpG control, the lytic peptide.  
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CHAPTER THREE 
A Simple and Cost-Effective Design of Peptoid Side Chains to Promote the Diversity of BHLP 
Scaffolds. 
 
3.1 Purpose/Goal 
Peptoids are relatively inexpensive to synthesize from commercially available amines with high purity and 
reproducibility.  As a result, they have become an important scaffold for the synthesis of combinatorial 
libraries.  The greater structural diversity of the peptoid side chains can optimize target binding and improve 
hit optimization that can be used as lead compounds in drug design.  The positioning scanning library 
approach is used in efforts to develop a diverse combinatorial peptoid library using 24 primary amines with 
R-CH2- side chains, where there are 24
n (where n=4) possible combinations.  These primary amines will 
be used in the R1-R4 position in the innovative BHLP peptoid scaffold, used to screen potential binding 
sites on the surface of the target proteins.  The goal of this project was to design a generalized, simple 
scheme to synthesize structurally diverse primary amines terminated at the C-terminus with a carboxylate 
or N-alkylated amide functional groups, with optimized product yields and simplified purification methods.  
3.2 Introduction 
For over 20 years, peptoids have been considered a promising class of drugs that can possess efficacy, high 
specificity, and lower toxicity compared to small molecule drugs.  The only major drawback of peptoids is 
that they do not adopt a preferred secondary structure like peptides and small proteins.  This chapter 
describes the first beta-hairpin like peptoid (BLHP) scaffolds.  The peptoid side chains that are compatible 
with forming a beta-hairpin-like scaffold will display structurally diverse primary amine building blocks.  
Those peptoid side chains are interspersed with intramolecular hydrogen-bonding networks needed to form 
a self-assembling beta-hairpin-like secondary structure.  The main focus of this chapter is the synthesis of 
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peptoid side chains that are compatible with the peptoid synthesis to allow polar side chain with 
carboxylates and amides.  Statistically, a new drug motif emerging out of tens of thousands of compounds 
cost more than $1 billion to develop over the course of a decade2.  Small organic molecules have been 
revolutionized over the last decade, represented as personalized therapeutic targeted drugs that exploit the 
particular genetic dependencies and vulnerabilities of cancer cells.  However, apart from the synthesis of 
these organic small molecules, the pharmacodynamics and pharmacokinetics still remain a challenge to-
date where they are cleared through the kidneys not having adequate contact time for effective binding and 
therapy of the disease.  There are four main steps used in efforts to overcome these pharmacological 
problems but are time consuming and costly.  Similarly, antibodies are another molecular class of drugs 
that have been developed as high affinity and specificity drugs but are costly and are not able to reach 
intracellular targets.           
 Peptoids have emerged as potential therapeutic drugs, currently used as an alternative to peptide-
based pharmaceuticals that have been hindered by their rapid degradation.  Their ability to be synthesized 
from N-substituted glycine monomers on solid support (resin beads), facilitates an efficient, rapid and cost-
effective approach to drug development.  There are two simple chemical steps that involve the coupling of 
bromoacetic acid to the resin, replacing the bromide (a good leaving group) with a primary amine with R-
CH2- side chain.  Unlike peptides that are limited to 20 naturally occurring amino acid residues, the vast 
diversity of the amines drastically expands the possible chemical repertoire in the peptoid combinatorial 
library.  Screening of these libraries can quickly lead to large number of hits in a practical manner.    
The peptoid, BHLP, used in this study was pioneered by McLaughlin’s group as a transformative 
alternate to standard peptoids that lack of predictable conformations of the secondary structure.  BHLP 
scaffolds, Figure 3.1, were predicted to self-assemble into stapled cyclic beta-hairpin-like conformations, 
so during the screenings any hit found, the constraint is built into every library hit and hence would be 
compatible with that target’s binding1.  The positional scanning library method used for the screening of 
the combinatorial libraries is an adaptation of Houghten’s Tea-bag approach in which 4 different side chain 
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positions with 24 different R-CH2-groups within a screening library will be used, giving 24
4 (=331,776) 
possible combinations of the peptoid.    
 
Figure 3.1.  A generic BHLP scaffold with 3 stapled peptoid chains and R1-R4 – CH2- side chains. 
This modified Houghten’s method is carried out in polypropylene 96-well filter plates that provide 
a convenient in situ synthesis and screening environment on resin beads.  This facilitates repeated 
extracellular target screenings on resin to occur in the same wells where the synthesis is performed avoiding 
crushing of the beads.  Two libraries will be synthesized and screened using 6 well plates for two 
positionally distinct combinatorial libraries, to defined mixtures that are multiplexed two peptoid side 
chains at a time.  In the first library, the R1 and R2 position will be known and in library 2, R3 and R4 will 
be known which will allow us to determine the sequence of the peptoid in the wells that show positive for 
target-specific binding.   
Referring to Figure 3.2, for the first 24 wells, R1 would have the same R-CH2- side chain and R2 
reacted with each of the 24 side chains.  R3 and R4 would be an equimolar mixture of 1-24.  For example, 
Well A1 would contain the sequence R1= 1, R2 = 1, R3 = 1-24 and R4 = 1-24.  In knowing what is in position 
R1 & R2 and that there are 24 R-CH2- side chains with two possible positioning, there will be a total of 24
2 
(=576) combinations of the R1-R4 sequence.  There is the assumption that the primary amines have similar 
reaction rates due to the conserved functionality, R-CH2-NH2.  6 x 96 well filter plates are equivalent to 24 
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x 24 with 576 combinations for R1 = 1-24 and R2 = 1-24. In Library 2, the same method is employed, where 
R3 will have the same side chain for 24 wells and R4 will react with each one of the 24 side chains with R1 
and R2 having an equimolar primary amine mixture.  Again, using six 96 well plates, there 331,776 
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Figure 3.2: A representation of a standard 96-well filter plate used for the formatted positional scanning library method. 
This method is advantageous over one-bead-one-compound (OBOC) combinatorial library methods where 
the hit rates of 1/100,000-screened beads results in 25,000 different beads being typically screened at a 
time.  Due to the multiplexing, a greater diversity of the library can be screened at faster rates which 
compensates for a compound being displayed 1/576 (242)th of its pure concentration on the bead and only 
1152 wells (2 libraries x 6 x 96) need to be screened to determine the sequences of hits from the correlation 
of the positions from the two different libraries. Even with lower hit rates than unstructured peptoid 
libraries, we are expecting to get 1 hit per library screen using high-throughput mutiplate screening 
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methods.  Therefore, developing a comprehensive scheme that can be used to synthesize this diverse library 
is of utmost importance.  
3.3 Experimental Procedures 
3.3.1 Materials and Methods 
All reagents used in the synthesis of the primary amines were ACS grade obtained from commercial 
sources from Sigma-Aldrich, Chem-Impex International, Fischer Scientific or Alfa Aesar.  The reactions 
were carried out in solution phase and purified using Flash Chromatography and re-crystallization methods.  
Thin Layer Chromatography (TLC) was performed on glass plates, purchased from Merck Millipore, coated 
with 2.0 mm thickness of PLC silica gel 60Å.  All 1H and 13C NMR 1D experiments were carried out using 
JOEL 400 MHz spectrometer in CDCl3 unless stated differently, and chemical shifts measured in ppm (δ) 
relative to internal standard tetramethylsilane (TMS).  Mass spectra were obtained for the intermediate and 
final products using Mass-Lynx 4.1 SCN805 HPLC/MS.  Each sample (~10-100uM) was dissolved in 
HPLC grade methanol in a 2-mL mass spectroscopy vial.  The samples were pumped through 2695 HPLC 
pump gradient C18 Atlantis T3 3µM column (2.1 x 150 mm, 5 μM particle size) with eluents: A = 0.1% 
HCO2H in H2O, B = 0.1% HCO2H in H3CCN. The purifications were carried out using a gradient of 5-
100% Buffer B over 25 min with a flow rate 0.2 mL/minute ran in positive ion-mode adding 0.1% formic 
acid to the analyte solution to enhance protonation and increase sensitivity. 
Table 3.1: List of chemicals used in the synthesis of peptoid side chains.  
Name of Chemical Molecular Structure 
piperidine-4-carboxylic acid 
 
trans-4-(aminomethyl)cyclohexane-1-carboxylic acid 
 
z-glycine hydrochloric salt 
.HCl 
tert-butyl 4-aminobenzoate 
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tert-butyl 3-aminobenzoate 
 
tert-butyl glycinate 
 
diethylamine 
 
Potassium carbonate K2CO3 
Benzyl chloroformate  
 
tert-butyl alcohol  
 
Triethylsilane 
 
Dioxane  
 
N,N-Diisopropylethylamine (DIEA) 
 
N,N′-Diisopropylcarbodiimide (DIC) 
 
Thionyl chloride 
 
Tetrahydrofuran (THF) 
  
4-Dimethylaminopyridine (DMAP) 
 
 
Dichloromethane (DCM) 
 
Methanol (MeOH)  
Ethanol (EtOH)  
Ethyl acetate (EtOAc) 
 
Hexane (Hex)  
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3.3.2 Schematic Overview of Peptoid Side Chains Synthesis  
 
Scheme 3.1 Generalized scheme to synthesize peptoid side chain from a secondary amino carboxylic acid (a) 1.0 eq. piperidine-4-
carboxylic acid, 2.0 eq. Benzyl Chloroformate, 10% Potassium Carbonate, 50%:50% 1,4-dixoane: water, 0oC to r.t. (b) 1.0 eq. SM, 
15 eq. thionyl chloride r.t to reflux (c) 1.0 eq. SM, 3.0 eq. tert-butyl alcohol, 2.0 eq. DIEA, cat. DMAP, DCM, 0oC to r.t. (d) 
Deprotection:1.0 eq. SM, 10 eq. triethylsilane, Pd/C, Methanol, r.t. (e) 1.0 eq. SM, 1.3 eq. Z-glycine, 1.3 eq. DIC, 4.O eq. DIEA, 
1.3 eq., DMAP, THF, r.t. (f) Deprotection:1.0 eq. SM, 10 eq. triethylsilane, Pd/C, Methanol, r.t. 
 
 
Scheme 3.2. Generalized scheme to synthesize peptoid side chain from a primary amino carboxylic acid (a) 1.0 eq. piperidine-4-
carboxylic acid, 2.0 eq. benzyl chloroformate, 10% potassium carbonate, 50%:50% 1,4-dixoane: water, 0oC to r.t. (b) 1.0 eq. SM, 
15 eq. thionyl chloride, r.t. to reflux (c) 1.0 eq. SM, 3.0 eq. tert-butyl alcohol, 2.0 eq. DIEA, cat. DMAP, DCM, 0oC to r.t. (d) 
Deprotection:1.0 eq. SM, 10 eq. triethylsilane, Pd/C, Methanol, r.t. 
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Scheme 3.3. Cbz-protected glycine and amino t-butyl ester coupling and deprotection (a) 1.0 eq. SM, 1.3 eq. Z-glycine, 1.3 eq. 
DIC, 4.O eq. DIEA, cat. DMAP, THF, r.t, (f) Deprotection:1.0 eq. SM, 10.0 eq. triethylsilane, Pd/C, Methanol, r.t. 
 
Scheme 3.4. Cbz-protected glycine and diethylamine coupling and deprotection. (a) 1.0 eq. SM, 1.3 eq. diethylamine, 1.3 eq. DIC, 
4.0 eq. DIEA, cat. DMAP, THF, r.t, (f) Deprotection:1.0 eq. SM, Pd/C, H2 (g), Methanol, r.t. 
 
Scheme 3.5. Generalized scheme to synthesize peptoid side chain from unprotected amino carboxylic acids (a)  1.0 eq. SM, 1.3 eq. 
dimethylamine, 1.3 eq. DIC, 4.0 eq. DIEA, cat. DMAP, THF, r.t, (f) Deprotection:1.0 eq. SM, Pd/C, H2 (g), Methanol, r.t. 
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3.3.3 Peptoid Side Chains Synthesis and Purification 
 
1-2 a 
Starting material (1.0 eq.) was dissolved in 10% K2CO3 and water: dioxane mixture (50:50, v/v) at rt. and 
then cooled to 0oC.  Benzyl chloroformate (2.0 eq.) was added dropwise and mixture was stirred for 18 h.  
The reaction mixture was cooled to 0oC and acidified with 1M HCl until pH 3.  The crude white solid was 
filtered and washed with water, ethanol and diethyl ether and further purified by recrystallization to yield 
pure white crystals. 
 
1a 
Product yield, 83.2%.  HPLC-MS m/z (ESI) for C14H17NO4 mw. 263.12 [M+H] 264.3.  
1H NMR (400 MHz, 
CDCl3), 7.375-7.247 (m, 5H), 5.118 (s, 2H), 4.071 (d, J = 10.0 Hz, 2H), 2.977 – 2.917 (t, J = 12.0 Hz, 2H), 
2.542-2.480 (m,1H), 1.935-1.904 (d, J = 12.0 Hz, 2H), 1.711-1.623 (q, 2H).  13C NMR (101 MHz, CDCl3), 
179.920, 155.312, 136.750, 128.595, 128.125, 127.982, 67.304, 43.232, 40.664, 27.717.  
 
1-2b 
Starting material (1.0 eq.) was suspended in freshly distilled thionyl chloride (15 eq.) and refluxed for 4 
hours.  The reaction mixture was then cooled to room temperature and the reflux condenser was replaced 
by a distillation bridge and the excess of thionyl chloride is removed by distillation under reduced to yield 
a yellow crude solid.  No further purification was required.   
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1-2c 
The crude product (1.0 eq.), tert-butyl alcohol and a catalytic amount of 4-dimethylaminopyridine was 
dissolved in dichloromethane and cooled to 0oC.  DIEA (2.0 eq.) was added dropwise and stirred for 18 h. 
The reaction mixture was washed with 5% citric acid, 5% Sodium bicarbonate, and then brine.  The organic 
layer was separated, dried over sodium sulfate and concentrated.  The crude product was recrystallized to 
yield pure white crystals.   
 
1c 
Product yield, 46.5%.  HPLC-MS m/z (ESI) for C18H25NO4 mw. 319.18 [M+H] 320.4.  
1H NMR (400 MHz, 
CDCl3), 7.308 (m, 5H), 5.110 (s, 2H), 4.037 (d, J = 13.2 Hz, 1H), 2.943-2.882 (t, J =12.0 Hz, 2H), 2.347 
(m, 1H), 1.825 (d, J= 12.8 Hz, 2H), 1.649-1.585 (m, 2H), 1.423 (s, 9H).  13C NMR (101 MHz, CDCl3), 
173.816, 155.274, 136.894, 128.556, 128.049, 127.934, 80.557, 67.160, 43.366, 41.929, 28.129, 28.053. 
 
2c 
Product yield, 35.4%.  1H NMR (400 MHz, CDCl3), 7.352-7.304 (m, 5H), 5.564 (bs, 1H), 5.115 (s, 2H), 
4.229 (m, 1H), 4.101 (d, J = 4.8 Hz, 2H), 3.942 (m, 1H), 1.410 (m, 8H), 1.166 (s, 9H).  13C NMR (101 
MHz, CDCl3), 169.944, 156.596, 136.261, 128.624, 128.298, 128.164, 67.227, 48.224, 44.506, 42.992, 
29.778, 22.533, 20.885. 
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1-2d 
Starting material (1.0 eq.) was dissolved in methanol and catalytic 5% Pd on carbon support was added.  
Triethylsilane (10.0 eq.) was added dropwise and the generated hydrogen gas was trapped with a balloon-
covered syringe.  The reaction was monitored by TLC. The reaction was then filtered over celite and 
concentrated.  The crude product was dissolved in dichloromethane further purified by acid-base extraction 
using 1M hydrochloric acid and 1M sodium hydroxide.  The organic layer was extracted using DCM, dried 
with sodium sulfate and concentrated to yield pure white crystals.  
 
1d 
Product yield, 82.2%. 1H NMR (400 MHz, CDCl3), 7.248 (bs, 1H), 3.354-3.320 (m, 2H), 3.032-2.984 (t, J 
=9.2 Hz, 2H), 2.496 – 2.475 (m, 1H), 2.156-2.032 (m, 4H), 1.423 (s, 9H). 13C NMR (101 MHz, CDCl3), 
171.832, 81.582, 76.781, 42.781, 38.900, 28.091, 24.756. 
 
1-5e 
Starting material (1.0 eq.), Z-glycine (1.3 eq.), and a catalytic amount of DMAP was dissolved in THF.  
DIC (1.3 eq.) was added dropwise and followed by DIEA (4.0 eq.) was added dropwise at 0oC to rt. and 
stirred for 18 h.  The organic layer was separated, dried over sodium sulfate and concentrated.  The crude 
product was recrystallized to yield pure white crystals.   
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2e 
Product yield, 54.1%.  1H NMR (400 MHz, CDCl3), 7.304 (m, 5H), 5.678 (bs, 1H), 5.092 (m, 3H), 4.598 
(m, 1H), 4.233 (m, 1H), 4.063 (d, J = 4.4 Hz, 2H), 3.944 (m, 1H), 1.955 (bs, 1H), 1.356 (m, 8H), 1.148 (m, 
9H).  13C NMR (101 MHz, CDCl3), 169.686, 156.720, 153.088, 136.280, 128.997, 128.863. 128.604, 
128.269, 128.116, 69.489, 67.179, 67.026, 48.157, 48.042, 44.343, 22.447, 20.808, 20.741. 
 
3e 
Product yield, 67.6%.  HPLC-MS m/z (ESI) for C16H22N2O5 mw. 322.1 [M+H] 323.2.  
1H NMR (400 MHz, 
CDCl3), 7.312 (m, 5H), 5.120 (s, 2H), 5.445 (bs, 1H), 3.919 (m, 4H), 1.453 (s, 9H). 
13C NMR (101 MHz, 
CDCl3), 169.024, 168.04, 128.643, 128.336, 128.212, 82.655, 67.352, 42.005, 28.101. 
 
4e 
Product yield, 53.7%.  HPLC-MS m/z (ESI) for C21H24N2O5 mw. 384.17 [M+H] 385.3.  
1H NMR (400 
MHz, CDCl3), 7.904 (d, J = 8.0 Hz, 2H), 7.526 (d, J = 8.0 Hz, 2H), 7.342 (m, 4H), 5.56 (s, 2H), 4.022 (s, 
2H), 1.572 (s, 9H). 13C NMR (101 MHz, CDCl3), 167.472, 165.191, 141.302, 135.753, 130.684, 128.739, 
128.528, 128.183, 118.955, 81.045, 76.781, 67.687, 44.5, 28.292. 
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5e 
Product yield, 57.4%.  HPLC-MS m/z (ESI) for C21H24N2O5 mw. 384.17 [M+H] 385.5.  
1H NMR (400 
MHz, CDCl3), 8.754 (bs, 1H), 7.986 (bs, 1H), 7.842 (d, J=8.4 Hz, 1H), 7.699 (d, J=7.6, 1H), 7.339-7.245 
(m, 5H), 5.969 (bs, 1H), 5.130 (s, 2H), 4.058 (bs, 1H), 1.548 (s, 9 H). 13C NMR (101 MHz, CDCl3), 167.721, 
165.479, 157.132, 132.773, 129.036, 128.036, 128.336, 128.058, 125.452, 124.225, 120.881, 81.457, 
67.485, 45.455, 28.225.  
 
1-5f 
Starting material (1.0 eq.) was dissolved in methanol and catalytic amount of 5% Pd on carbon support was 
added.  Triethylsilane (10.0 eq.) was added dropwise and the generated hydrogen gas was trapped.  The 
reaction was monitored by TLC. The reaction was then filtered over celite and concentrated.  The crude 
product was dissolved in dichloromethane further purified by acid-base extraction using 1M hydrochloric 
acid and 1M sodium hydroxide.  The organic layer was extracted using DCM, dried with sodium sulfate 
and concentrated to yield pure white crystals.  
 
1f 
Product yield, 92.5%.  HPLC-MS m/z (ESI) for C12H22N2O2 mw. 242.16 [M+H] 243.2.  
1H NMR (400 
MHz, CDCl3), 4.301 (m, 1H), 3.875 (m, 1H), 3.798 (m, 5H), 1.421 (bs, 1H), 1.401 (m, 4H), 1.135 (s, 9H). 
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2f 
Product yield, 81.6%.  1H NMR (400 MHz, CDCl3), 6.929 (bs, 1H), 6.304 (bs, 1H), 5.692 (d, J= 7.2, 1H), 
4.245 (m, 1H), 3.827 (m, 1H), 3.728 (d, J= 6.0, 2H), 1.477-1.190 (m, 8H), 1.54 (m, 9H).  13C NMR (101 
MHz, CDCl3), 171.736, 170.433, 53.936, 44.228, 43.596, 42.197, 42.015, 41.449. 29.720, 23.501, 23.338, 
22.543.  
 
3f 
Product yield, 86.3%.  HPLC-MS m/z (ESI) for C8H16N2O3 mw. 188.14 [M+H] 189.20.  
1H NMR (400 
MHz, CDCl3), 3.873 (s, 2H), 3.308 (s, 2H), 1.696 (s, 2H), 1.159 (s, 9H).  
13C NMR (101 MHz, CDCl3), 
173.116, 169.178, 82.119, 44.698. 41.536, 28.062.   
 
4f 
Product yield, 85.3%.  HPLC-MS m/z (ESI) for C13H18N2O3 mw. 250.13 [M+H] 251.3.  
1H NMR (400 
MHz, CDCl3), 7.912 (d, J= 8, 2H), 7.628 (d, J = 8.8, 2H), 3.552 (s, 2H), 1.549 (s, 9H).  
13C NMR (101 
MHz, CDCl3), 165.441, 141.359, 130.674, 127.483, 118, 514, 80.592, 44.947, 28.283, 28.082. 
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5f 
Product yield, 80.2%.  HPLC-MS m/z (ESI) for C13H18N2O3 mw. 250.13 [M-NH3
+] 236.2.  1H NMR (400 
MHz, CDCl3), 9.498 (bs, 1H), 7.956 (s, 2H), 7.686 (d, J = 10.4 Hz, d), 7.676 (t, J = 8.2, 1H).  3.441 (s, 2H), 
1.558 (s, 9H).  13C NMR (101 MHz, CDCl3), 171.152, 165.469, 137.833, 132.821, 129.036, 125.049, 
123.535, 120.220, 81.285, 45.196, 282.35. 
 
 
6a 
Benzyl (2-(dimethylamino)-2-oxoethyl)carbamate.  ((Benzyloxy)carbonyl) glycine (5.00 g, 23.9 mmol) 
and a catalytic amount of 4-dimethylaminopyridine were dissolved in THF (100 mL) at r.t.  Diethylamine 
(3.21 mL, 31.1 mmol) was added dropwise and the solution was cooled to 0oC.  N,N′-
Diisopropylcarbodiimide (4.81 mL, 31.1 mmol) and then DIEA (15.8 mL, 95.6 mmol) were added and 
stirred for 24 hr.  The reaction mixture was filtered over celite and concentrated.  The crude oil was 
dissolved in ethyl acetate (100 mL) and washed with saturated citric acid (20 mL, x3), saturated sodium 
carbonate (20 ml, x3) and brine (20 ml, x3).  The organic layer was collected, dried over sodium sulfate 
and concentrated.  A minimal about of dichloromethane was added to the crude product to filter the excess 
urea and then concentrated to yield a yellow solid.  The crude solid was triturated with minimal volume of 
diethyl ether and recrystallized with ethanol to yield white crystals, 7a (2.45g) in 43.4% yield.  1H NMR 
(400 MHz, CDCl3), 7.340 (m, 5H), 5.566 (bs, 1H), 5.112 (s, 2H), 4.087 (s, 2H), 1.390 (m, 4H), 1.183 (t, 
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J=6.4 Hz, 6H). 13C NMR (101 MHz, CDCl3), 156.59, 153.098, 136.5, 128.614, 128.298, 128.154, 67.217, 
44.497, 42.983, 20.885.   
 
 6b  
2-amino-N,N-dimethylacetamide. Benzyl (2-(dimethylamino)-2-oxoethyl) carbamate (2.0 g, 8.47 mmol) 
was dissolved in methanol and a catalytic amount of 10 wt % Pd/C was added.  The starting material was 
shaken on a hydrogenator with a positive pressure of H2 (g) for four (4) hours.  The product was filtered 
over celite, concentrated and dried on high vacuum for 24 hr. to yield a white solid, 6b (0.828 g) in 95.7% 
yield.  
 
 
Starting material (1.0 eq.) was dissolved in 10% potassium carbonate and water: dioxane mixture (50:50, 
v/v) at rt. and then cooled to 0oC.  Benzyl chloroformate (2.0 eq.) was added dropwise and mixture was 
stirred for 18 h.  The reaction mixture was cooled to 0oC and acidified with 1M Hydrochloric acid until pH 
3.  The organic layer was extracted with DCM and washed with brine (x2), dried over Na2SO4 and 
concentrated.  Both entries were cooled to 0oC and ethyl acetate, ether and hexane (1:1:1, v/v) were added 
and stirred.  Entry 8a precipitated out and the filtered crude white product was triturated with diethyl ether 
and further purified by recrystallization to yield pure white crystals in 85.3% yield.  1H NMR (400 MHz, 
DMSO), 12.160 (bs, 1H), 7.307 (m, 5H), 4.969 (s, 2H), 3.177 (d, J=5.2 Hz, 2H), 2.350 (t, J= 3.2 Hz, 2H).  
13C NMR (101 MHz, DMSO), 173.270, 156.548, 137.689, 128.873, 128.250, 64.742, 37.061, 34.674. 
No precipitate was formed in entry 9a.  The mixture was concentrated, and the crude oil was purified by 
flash chromatography using EtOAc/Hex (30:70, v/v) to elute a white solid, 9a in 79.4% yield. 1H NMR 
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(400 MHz, CDCl3), 12.174 (s, 1H), 7.307 (m, 5H), 4.974 (s, 2H), 3.182 (dd, Jab =6.0 Hz, Jac = 13.2 Hz, 
3H), 2.650 (t, J = 6.4 Hz, 2H), 2.465 (m, 1H), 2.356 (t, J = 6.8 Hz, 1H). 13C NMR (101 MHz, CDCl3), 
175.938, 175.665, 156.596, 128.614, 128.212, 128.058, 66.777, 43.347, 37.741, 29.701,28.474. 
 
7-8 b 
Starting material (1.0 eq.), dimethylamine hydrochloride salt (1.3 eq.) and a catalytic amount of DMAP 
were dissolved in THF at r.t.  and the solution was cooled to 0oC.  DIC and DIEA were added dropwise and 
stirred for 24 hr.  The reaction mixture was filtered over celite and concentrated.  The crude oil was 
dissolved in ethyl acetate and washed with saturated citric acid, saturated sodium carbonate and brine.  The 
organic layer was collected, dried with Na2SO4 and concentrated.  A minimal about of dichloromethane 
was added to the crude product to filter the excess urea and then concentrated to yield a yellow oil.     
 
7-8 c 
Starting material (1.0 eq.) was dissolved in methanol and a catalytic amount of 10% Pd/C was added.  The 
starting material was shaken on a hydrogenator with a positive pressure of H2 (g) for four (4) hours.  The 
product was filtered over celite, concentrated and dried on high vacuum for 24 hr. to yield a colorless oil. 
3.4 Results and Discussion  
3.4.1 BHLP Scaffold Design 
The BHLP scaffold synthesis is schematically similar to peptoid synthesis, apart from the three side 
chains incorporated into the scaffold to facilitate the desired self-assembled cyclic beta-hairpin, that 
undergo tandem copper catalyzed click reaction.  The scaffold will be synthesized on amino Tentagel beads 
reacted with a linker terminated with a carboxylate to give a stable bead linkage. Once a hit is found, the 
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individual sequence will be synthesize using a Rink Amide link to allow removal during the 90% TFA 
cleavage step.1  
Steps 1-8 are identical for all the library members to give the starting scaffold outlined in Figure 
3.3, which will be verified before the combinatorial libraries are prepared.  The starting material will be 
cleaved from aliquots of the resin to verify the purity of the desired product by HPLC-MS and MALDI-
TOF-MS.  Studies conducted by McLaughlin’s group using the unstapled version of related scaffolds found 
2,4-dimethoxylbenylamine (DMB-NH2), used to make the protected glycine units, gave cleaner yields than 
using protected glycine.  This is due to the repetitive use of the highly reactive bromoacetic anhydride 
which gave significant diacylation of the sterically unhindered secondary amide backbone, which is not 
present in standard peptoids because the lack of hydrogen bonding.  During the 90% TFA deprotection step, 
to unmask the glycine protons, the DMB protecting group is cleanly removed due to the two strong electron 
donors into the aromatic ring.   
  
 
Figure 3.3 The starting material for the combinatorial library.  
3.4.2 Peptoid Side Chains Design  
Referring to Figure 3.4, in step 10, the R-CH2-NH2 peptoid side chains require the carboxylic acid 
to be protected with an acid labile protecting group (t-butyl) to ensure chemoselectivity in the subsequent 
reactions coupling to the BHLP scaffold.  This protecting group is removed during the final deprotection 
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step with 90% TFA.  The synthesis of the tert-Butyl esters was performed in three steps compared to the 
one-pot esterification method typically used.   In previous efforts, outlined in Scheme 3.6, acid-catalyzed 
esterification was attempted with the unprotected N-group of the primary amines.  An equivalence of 1.3 
concentrated sulfuric acid was used to fully pronate the amino group and the initiate the esterification 
reaction.  The Dean-stark trap was used to remove the water molecules to shift the reaction equilibrium to 
the right to favor the products.  However, in spite of efforts employed to extract the product, the average 
reaction yields were 18.6%.   
 
Scheme 3.6. Acid-catalyzed esterification of peptoid side chains. 
Solubility of the starting material in polar aprotic solvents was another challenge faced.  Mixtures 
of low boiling solvents, such as dioxane and THF were used with little success in dissolving the more polar 
starting materials.  Minimal amount of water was used to dissolve glycine, but resulted in yields < 10%.   
 In an alternative strategy, the amino group was protected with Cbz, followed by the activation of 
the carboxylic acid using DIC, and a cat. amount of DMAP in the presence of DIEA, shown in Figure 3.4. 
 
Figure 3.4.  Undesired N-isopropyl-N-(isopropylcarbamoyl) amide formed in Entries 9a-9c. 
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However, because the hydroxyl group of t-BuOH is a poor nucleophile, compared to amines used in the 
standard amide bond formation, the major product formed in entries 9a-9b, was a N-isopropyl-N-
(isopropylcarbamoyl)amide.  The undesired side product formed using this method, outlined in the 
proposed mechanism, Figure 3.1, was confirmed with HPLC-MS and NMR summarized in Table 3.2.   
 
Figure 3.5. Proposed mechanism of the undesired product formed using DIC as the activating group. 
The mass spectra were consistent for all three entries showing the base peak of the fragment ions with the 
removal of N-isopropylformamide (mw = 87.07) from the parent ion.   
Table 3.2. Reaction yield %, HPLC-MS and NMR peaks of three entries from the direct coupling of the 
carboxylic acid and t-BuOH 
Entry Yield (%)        HPLC-MS   Confirmation peaks (400 MHz NMR) 
   Calcd.         Found   1H            13C  
 
9a 36.7 397.20 313 4.334 (m, 1H), 3.792 (m, 1H), 1.386 
(d, J = 8.4, 6H), 0.997 (d, J = 8.4, 6H) 
42.753, 22.361 
9b 38.8 411.22 327 4.414 (m, 1H), 3.857 (m, 1H), 1.358 
(d, J = 6.8, 6H), 1.013 (d, J = 6.8, 6H) 
42.743, 22.399 
9c 59.9 349.20 265.3 
250.3 
4.213 (m, 1H), 3.959 (m, 1H), 1.315 
(d, J = 6.8, 6H), 1.188 (d, J = 5.2, 6H) 
42.829, 22.619 
 
 
In the revised scheme, the starting materials were Cbz-protected and purified using recrystallization 
methods, to give an average reaction yields of 82.93% summarized in Table 3.3, and were refluxed with 
thionyl chloride to form acyl chlorides, finally coupled to the t-BuOH to yield the desired product.  Without 
the use of carbodiimide activating reagents, purification methods were simplified, since carbamide (urea) 
side products were not formed.  
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Table 3.3: % yield for isolated intermediates Cbz-protected amino carboxylic acids entries. 
 
 Entry               Product          Yield (%)                 Entry            Product                       Yield (%)    
  
     
 
1a 
 
 
 
83.2 
  
7a 
           
 
85.3 
 
 
2a 
 
 
 
83.8 
  
8a 
             
 
 
79.4 
 
 
 
The reflux with thionyl chloride is an acceptable method for the conversion of sterically hindered carboxylic 
acids to their acid chlorides.  The excess reagent was removed under vacuum fractional distillation.  Toluene 
was added to the reaction mixture at increment volumes to ensure the complete removal of thionyl chloride 
as no further purification of the acid chloride was done.  In the same reaction flask, the acyl chloride was 
coupled to t-BuOH simplifying the generalized scheme that reported average of 41.0%.  We were concerned 
with racemization at Entry 2 seen after the Cbz protection and therefore after each step, apart from the 
formation of the acyl chloride, the intermediate products were purified with flash chromatography to report 
one diastereomeric pure products.   
 The positional scanning library method prosed by McLaughlin, hypothesized that the peptoid side 
chains would have the same rate of reaction in assembling the BHPL scaffolds.  In entries 1-6, the R-CH2-
NH2 unit was synthesized by amide bond formation between the R- peptoid side chain and Cbz-glycine 
followed by deprotection of the Cbz protecting group. There are a plethora of strategies and method 
developed for amide bond formation.  In efforts to simplify the general scheme while optimizing reaction 
yields and improving selectivity, DIC activating reagent, DIEA and cat. amount of DMAP reagents were 
used to successfully yield crystalline products.  Entries 7-8 were used to conduct studies on the crystalline 
properties of extending the CH2- groups of the peptoid side chains.  We saw a decrease in the rigidity of 
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the side chains from their inability to form crystalline products, as well as lower reaction yields in the amide 
bond formation with dimethyamine.    
Table 3.4. % yield of amide bond formation in Entries 1-8.  
 Entry                Product    Yield (%)        Entry                Product         Yield (%)                                       
 
1e 
 
 
 
 
 
 
50.1 
 
  
5e 
 
 
 
57.4 
 
2e 
 
 
  
54.1   
6b 
 
43.4 
 
3e 
 
 
 
 
 
 
67.6 
  
7b 
 
35.6 
 
4e 
 
 
 
 
 
 
 
 
53.7 
  
7b 
 
 
 
34.1 
 
 
In determining the peptoid side chains, we selected starting amino carboxylic acids that were 
structurally diverse and rigid to yield crystalline products.  This would limit flash chromatography being 
used to purify the intermediate products and final primary amines in the multi-step scheme.  In the Cbz-
deprotection to unmask the primary amine, two methods were studied; the in-situ generation of H2(g) by 
addition of triethylsilane to Pd on carbon support and H2 (g) pumped through a hydrogenator.  Both methods 
resulted in rapid and efficient reduction of multiple bonds, however, cleaner reactions and higher yields 
were seen with the use of the hydrogenator, summarized in Table 3.5, after filtration over celite.      
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Table 3.5: % yield for final primary amines of Entries 1-8 for both Cbz-deprotection methods. 
 
  Hydrogenator       Triethylsilane 
Entry                Product    Yield (%)       Entry                Product            Yield (%)                                       
 
1f 
 
 
 
92.5 
 
1d 
 
 
 
82.2 
 
6f 
 
 
95.7 
 
2d 
 
 
79.8 
7f 
 
 
92.4 
 
2f 
 
 
81.6 
8f 
 
 
91.9 
 
3f 
 
86.3 
    
4f 
 
85.3 
   5f 
 
80.2 
  
Conclusion  
The generalized schemes outlined in Scheme 3.1-3.5 were successful in synthesizing 8 different peptoid 
side chains with structural diversity.  The yields for the Cbz protection were reproducible in 4 different 
entries, an average of 82.6%, consistent with literature values9.  Protection of the carboxylic acid with acid 
labile t-butyl initially posed to be a challenge with obtaining the esters but the revised scheme, converting 
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the carboxylic group to an acyl chloride, simplified purification methods and obtained the desired products 
with an average yield of 41.0%. We conducted research for commercially available amino t-butyl esters to 
limit the multi-step procedure to synthesize new compound entries, however these esters were drastically 
costlier. The advantages of using t-butyl esters compared to methyl or ethyl esters, are such that they are 
more stable as free bases and can be stored for extended time.             
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CHAPTER FOUR: 
A PROTOTYPE OF BRACHYTHERAPY BEADS USED IN HIGH-DOSE RADIOTHERAPY 
4.1 Purpose/Goal 
Internal radiation therapy is another type of cancer treatment used in localized tumors.  Previous radiation 
therapy methods used gamma-particle and beta-particle emitters much more frequently than alpha-particles.  
In brachytherapy treatment, alpha-particles were not used as a radiation source because they would be 
completely encapsulated and could not be emitted from the beads.  The focus of this chapter is to synthesize 
a representation of brachytherapy beads that could encapsulate radioactive materials that would produce 
alpha-particle emitters confined to a few cell diameters of where the beads are placed.  Using Tentagel 
macrobeads, the surface can be coated with DOTA chelators that coordinates to radioactive material and 
used to treat tumors locally, with high-dose radiation (HDR) and limiting damage to surrounding tissues 
more than 2-10 cell diameters away.  This will be a useful method is treating local cancers that have not 
metastasized and in crucial areas of the body where there are high surgical risks.  Brachytherapy offers a 
quicker, more effective type of radiation treatment for some cancers.    
4.2 Introduction 
In the fight against cancers, researchers are becoming more strategically aggressive in designing alternate 
treatment methods.  Depending on the type of cancer, radiation therapy, high doses of radiation, may be a 
viable option used in killing the cancer cells and shrinking tumors, by damaging their DNA.  This prevents 
them from growing further; eventually dying where they are then broken down and removed by the body.  
This process may take weeks or months after the last course of radiation therapy.  For some patients, 
external radiation may be the only option of treatment, used to shrink localized tumors from outside the 
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body to relieve pain, shortness of breath and other problems caused by the tumor.  This is a local course of 
treatment that may also damage healthy tissue and cause other complications.   
Internal radiation therapy, a treatment involving the injection of a source, solid or liquid, of 
radiation near or directly into the tumor.  A liquid source of radiation, called systemic therapy – treatment 
that travels intravenously triggering cell death – is useful in metastatic tumors; whereas, solid source 
radiation (brachytherapy) treats localized tumors.  Radiotherapy, maybe coupled with other cancer 
treatments, such as chemotherapy, immunotherapy and surgery.  When combined with surgery, radiation 
maybe used before the procedure to shrink the size of the cancer to allow for easy removal and reduces the 
chances of it returning.  Radiation can also be used during surgery as intraoperative radiation or after to kill 
any cancer cells that remain. 
 Cancer often affects tissue and vital organs, it is important for radiation therapy to be precisely 
focused on the tumors in efforts to minimize side effects.  Brachytherapy ensures the high-dose radiation 
given from implants to cancerous tissue while reducing exposure to surrounding healthy tissue.  With this 
method, tiny, hollow catheters are inserted directly into the tumor, temporarily, which are check 
periodically prior to treatment.  The brachytherapy beads are then inserted into each catheter guided by 
computational controls to precisely target the location of the tumors and the length of time the beads stay 
within the catheter to release the radiation dose.  HDR brachytherapy can provide precise treatment within 
only a few minutes up to 1-2 days depending on the type and stage of the cancer.            
4.3 Experimental Procedures 
4.3.1 Materials and Methods 
Reagents were ACS and HPLC grade obtained from commercial sources from Sigma-Aldrich and 
Chem-Impex International and used without further purification.  Reactions carried out in solution phase 
were purified using Flash Chromatography.  Thin Layer Chromatography (TLC) was performed on glass 
plates, purchased from Merck Millipore, coated with 2.0 mm thickness of PLC silica gel 60Å.  1H and 13C 
NMR 1D experiments were carried out using JOEL 400 MHz spectrometer in CDCl3 unless stated 
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differently, and chemical shifts measured in ppm (δ) relative to internal standard tetramethylsilane (TMS).  
TentaGel S NH2 resins (capacity: 0.26 mmol/g, size: 90 µm) were purchased from Rapp Polymere.  The 
Substitution levels were monitored using Varian Cary 50 UV-Vis spectrophotometer. 
Table 4.1: List of chemicals used in the synthesis of peptoid side chains.  
Name of Chemical Molecular Structure 
TentaGel®MB NH2 Resin  
 
Fmoc-Lys(Boc)-OH 
 
Dansyl Chloride 
 
2-(6-Chloro-1-H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate (HCTU) 
 
Acetic Anhydride (CH3CO)2O 
 
N,N-Diisopropylethylamine (DIEA)  
 
2-(6-Chloro-1-H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate (HCTU) 
 
Acetic Anhydride 
 
Piperidine 
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Europium (III) Chloride Hexahydrate  EuCl3.6H2O 
Glycine tert-butyl ester hydrochloride 
 
.HCl 
Tetrahydrofuran (THF) 
 
Acetonitrile  CH3CN 
 
4.3.2 Schematic Overview of Brachytherapy Beads 
The TentaGel resin was swelled in water for 48 h to expose a small fraction of the exterior primary 
amines.  The solvent was exchanged with a Et2O: DCM mixture to expose all exterior primary amines and 
3% of FmocOSu was charged to the resin to give the desired substitution level, 1%.  The resin was washed 
with multiple solvents then swelled in DCM and further treated with acetic anhydride to cap all interior and 
unreacted exterior amines.  The Fmoc was then deprotected in 25% piperidine: NMP and Fmoc-Lys(Boc)-
OH was coupled to the resin and shown in Scheme 4.1. 
 
Scheme 4.1. Deprotection of Fmoc and Fmoc-Lys (Boc)-OH coupling. (a) 25 % piperidine: NMP. (b) 1.0 eq. Resin, 3.0 eq Fmoc-
Lys(Boc)-OH, 3.0 eq HCTU, 6.0 eq DIEA in NMP 
An aliquot of the resin is dried on the lyophilizer and the substitution level was calculated.  The amino 
group of the lysine is then unmasked, and the resin is charged with dansyl chloride outlined in Scheme 4.2.  
dansyl chloride was also reacted with glycine tert-butyl ester hydrochloride in solution phase and purified 
by flash chromatography to yield a standard reagent to quantify the amount of dansyl that was coupled to 
the resin.  
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Scheme 4.2. Fmoc-deprotection and dansyl chloride coupling. (a) 25% piperidine: NMP. (b) 1.0 eq. Resin, 6.0 eq. dansyl chloride, 
6.0 eq. DIEA in NMP.  
The resin was then treated with TFA to deprotect the Boc to couple the DOTA-tris (tert-butyl ester) chelator.     
 
Scheme 4.3. Boc deprotection and DOTA-tris (tert-butyl ester) coupling.  (a) TFA. (b) 1.0 eq. Resin, 3.0 eq. DOTA-tris (tert-
butyl ester), 6.0 eq. DIEA, 3.0 eq. HCTU in NMP. 
After hydrolysis of the t-butyl esters Europium (III) was coordinated to the ligand and further fluorescence 
studies will be conducted.  
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Scheme 4.4. tert-Butyl deprotection and europium (III) coordination.  (a) TFA. (b) 1.0 eq. Resin, 6.0 eq. 1.0 M sodium acetate-
acetic acid, pH 5 buffer.  
4.3.3 Downloading of TentaGel MB HN2 
 
 
 
The TentaGel-NH2 Resin (2.57g, 0.26 mmol/g) was taken in a 16-mL falcon tube and swelled in water (10 
mL) for 48 h.  The resin was then dried under vacuum filtration and then swelled in DCM and washed 3 
times with Et2O: DCM (45%:55%, v/v) to exchange the solvent.  Fmoc-OSu (6.76 mg, 3%) and DIEA (100 
µL, 0.605 mmol) were dissolved in the above solvent mixture.  The flacon tube was sealed, and Thermolyne 
Half-Size Speci-Mix was used for mixing the resin and reaction reagents for 24 h.  The resin was washed 
3 times with Et2O: DCM (45%:55%, v/v) and further washed with HPLC grade Acetonitrile for 1.5 h.  The 
resin was then dried on the lyophilizer for 24h. to remove any excess water molecules.  The resin was then 
swelled in freshly distilled DCM for 1h. and treated with acetic anhydride and diisopropylethane (3:2).  The 
reagents were drained, and the resin was washed with multiple solvents, DCM (x3), NMP (x3) and then 
anhydrous DCM (x3) and an aliquot of the resin was dried, and the loading levels were calculated using a 
standard curve with Fmoc-OSu (33.7 mg in 100 mL 20% Piperidine: 80% Methanol).    
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The resin (250 mg, 0.00260 mmol/g) was swelled in DCM for 1 h. Fmoc-Lys(Boc)-OH (0.914 mg, 0.00195 
mmol), HCTU (0.807 mg, 0.00195 mmol) and DIEA (0.645 µL, 0.0039 mmol) were dissolved in NMP (2 
mL) and coupled to the resin for 4 h.  The resin was washed with NMP (3 mL, x3) and DCM (3 mL, x3).  
An aliquot of the resin was dried (10.3 mg) and treated with 25% piperidine in NMP (200 µL) to cleave the 
Fmoc to yield 0.0784 mM, 58.57%. 
 
The resin (250 mg, 0.0026 mmol) was treated with TFA (3 mL) for 20 min.  The resin was washed with 
NMP (3 mL, x3), DCM (3 mL, x3), 10% DIEA in NMP, and DCM (3 mL, x3).  Dansyl chloride (1.05 mg, 
0.0039 mmol) and DIEA (0.645 µL, 0.0039 mmol) were dissolved in NMP and coupled to the resin for 4 
h.  The resin was washed with NMP (3 mL, x3) and DCM (3 mL, x3).   
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4.3.4 Coordination of Europium (III) Metal 
 
The resin (250 mg, 0.0026 mmol) was treated with TFA (3 mL) for 20 min.  The resin was washed with 
NMP (3 mL, x3), DCM (3 mL, x3), 10% DIEA in NMP, and DCM (3 mL, x3).  DOTA-tris (tert-butyl 
ester) (1.12 mg, 0.00195 mmol), HCTU (0.807 mg, 0.00195 mmol) and DIEA (0.645 µL, 0.0039 mmol) 
were dissolved in NMP (2 mL) and coupled to the resin for 4 h.  The resin was washed with NMP (3 mL, 
x3) and DCM (3 mL, x3).   
 
The resin (250 mg, 0.0026 mmol) was treated with TFA (3 mL) for 20 min.  The resin was washed with 
NMP (3 mL, x3), DCM (3 mL, x3), 10% DIEA in NMP, and DCM (3 mL, x3).  EuCl3.6H2O in 1.0M 
Sodium acetate-acetic acid, pH 5 buffer was added to the resin and left undisturbed for 24 h.   
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tert-Butyl ((5-(dimethylamino)naphthalen-1-yl)sulfonyl)glycinate, 6.  Glycine tert-butyl ester (0.106 g, 
0.632 mmol) and dansyl chloride (0.222 g, 0.822 mmol) was dissolved in a mixture of NMP and THF (1 
mL: 4 mL) and stirred vigorously at r.t  DIEA (0.418 mL, 2.53 mmol) was added dropwise and the reaction 
mixture was stirred for 4 h.  After all the Glycine tert-butyl ester was consumed, the THF was removed and 
the crude mixture was dissolved in ethyl acetate (15 mL) and washed with saturated citric acid (5 mL), 
saturated sodium carbonate (5 mL) and brine (5 mL).  The organic layer was collected, dried over sodium 
sulfate and concentrated.  The mixture was concentrated, and the crude oil was purified by flash 
chromatography using EtOAc/Hex (20:80, v/v) to elute a yellow, fluorescent solid, 6. 1H NMR (400 MHz, 
CDCl3), 8.550 (d, J=8.8 Hz, 1H), 8.326 (d, J=8.0 Hz, 1H), 8.237 (d, J= 7.6, 1H), 7.582 (t, 1H), 7.504 (t, 
1H). 7.200 (d, J=7.2 Hz, 1H), 5.188 (bs, 1H), 3.625 (s, 2H), 2.871 (s, 6H), 1.262 (s, 9H). 13 C NMR (101 
MHz, CDCl3) 167.673, 152.053, 130.799, 130.051, 129.774, 128.614, 123.200, 118.993, 89.924, 45.493, 
45.0662, 27.832.  
4.4 Results and Discussion 
  4.4.1 Loading Substitution Level 
The primary focus of this chapter was to synthesize a prototype of the brachytherapy bead on solid phase 
that would coordinate to a fluorescent metal to be able to quantify the concentration of the metal on the 
bead.  The studies reported are preliminary and more experimentation will be conducted to obtain 
reproductible results.  In the first coupling of the Fmoc-Lys (Boc)-OH, we assumed that 1% of the resin 
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was downloaded at 0.0026 mmol/g substitution level.  The Fmoc test was carried out using both Fmoc-OSu 
and Fmoc-Cl to determine the Molar absorptivity using 5 known concentrations shown in Table 4.2 and 
4.3.    
Table 4.2. Standard curve of the concentrations Fmoc-OSu against absorbance.   
         Fmoc-OSu       
Concentration (mM)    Vol. of Fmoc-OSu (µL)         Vol. of 20% Pip.:80% MeOH Absorbance 
0.000 0 200 0 
0.00625 25 175 0.0359 
0.0125 50 150 0.0762 
0.025 100 100 0.1554 
0.05 200 0 0.3182 
  
33.7 mg of Fmoc-OSu was dissolved in 100 mL of 20% Pip.:80% MeOH. All measured samples to diluted to a final volume of 4 
mL.  The UV-VIS spectrophotometer was blanked with 20% piperidine: 80% methanol. 
 
The same procedure was repeated with 25.9 mg of Fmoc-Cl to determine the reproducibility of the standard 
curve.  The molar absorptivity of Fmoc-OSu was reported as 6393.6 and Fmoc-Cl to be 7059.2, however, 
since the absorbance values were within the gradient line, 6393.6 was used to determine the concentration 
of Fmoc loaded onto the resin.   
Table 4.3. Standard curve of the concentrations Fmoc-Cl against absorbance at 301 nm.   
         Fmoc-OSu       
Concentration (mM)    Vol. of Fmoc-OSu (µL)         Vol. of 20% Pip.:80% MeOH Absorbance 
0.000 0 200 0 
0.00625 25 175 0.0466 
0.0125 50 150 0.0872 
0.025 100 100 0.1637 
0.05 200 0 0.3563 
 
 25.9 mg of Fmoc-Cl was dissolved in 100 mL of 20% Pip.:80% MeOH. All measured samples to diluted to a final volume of 4 mL.  
The UV-VIS spectrophotometer was blanked with 20% piperidine: 80% methanol. 
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Figure 4.1. Graph of Fmoc-OSu and Fmoc-Cl concentration against Absorbance at 301 nm 
 
The Fmoc was cleaved from 10.3 mg of the resin using 200 µL 20% Piperidine:80% Methanol and further 
diluted to 2000 µL to give an absorbance of 0.0501 and a calculated concentration of 0.0784 mM.  This 
was reported at 0.5857% of the resin.   
 We hypothesized that coupling dansyl chloride to the resin would result in another method of 
quantifying the loading level of the resin.  When dansyl chloride reacts with a primary amine the dansyl 
sulfonamide, an aliquot of resin (11.6 mg) was suspended in ethanol the fluorescence emission and 
excitation were measured; fluorescence emission spectrum (excitation at 340); excitation spectrum 
(emission at 510), shown in Figure 4.2. 
 
Figure 4.2. Fluorescence emission and excitation spectra of 11.6 mg of resin in absolute ethanol. Fluorescence emission spectrum 
(excitation at 340); excitation spectrum (emission at 510). 
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  4.4.2 Further Studies 
The concentration of dansyl loaded onto the resin will be determined from the dansyl sulfonamide 
standard reagent synthesized to construct a standard curve using fluorescence spectrophotometry.  The 
fluorescence spectrophotometer will also be used to determine the Eu (III) coordination.  The idea behind 
the development of the brachytherapy beads is to conduct studies on the loading levels beads after the resin 
was downloaded to 1% in efforts to limit the amount of radioactive material loaded onto the beads.     
 4.5 References 
1. Cheuck L., David Kim E.D. (2017), Brachytherapy (Radioactive Seed Implantation Therapy) in 
Prostate Cancer. Retrieved October 14th, 2017 from https://emedicine.medscape.com/article/453349-
overview 
2. Hudson R. (1999) Brachytherapy treatments increasing among Medicare Population. Health Policy 
Brief of the American Urologic Association, Inc.  
3. Mate T.P., Gottesman J.E., Hatton J., High dose-rate after loading 192 Iridium prostate 
brachytherapy: feasibility report. (1998) Radiation Oncology Biology Physics,41:525-533. 
4. National Cancer Institution. What to Know About Brachytherapy (A Type of Internal Radiation 
Therapy).  Retrieved October 26th, 2017 from https://www.cancer.gov/publications/patient-
education/brachytherapy.pdf  
5. Cancer Treatment Centers of America. What is High-dose rate (HDR) brachytherapy? Retrieved 
October 26th, 2017 from http://www.cancercenter.com/treatments/high-dose-rate-brachytherapy/ 
6. Wang X., Peng L., Liu R., Xu B., Lam K.S. (2005) Applications of topologically segregated bilayer 
beads in ‘one-bead one-compound’ combinatorial libraries. J. Peptide Res., 65, 130–138. 
7. Wanichacheva N., Watpathomsub S., Sanghiran V., and Grudpan K. (2010) Synthesis of a Novel 
Fluorescent Sensor Bearing Dansyl Fluorophores for the Highly Selective Detection of Mercury (II) Ions. 
Molecules 15, 1798-1810. 
  
92 
 
 
 
 
 
 
 
APPENDIX A: Selected LC-MS, MALDI-MS and Q-TOF Spectra for CpG-Lytic Peptide 
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Method Info: Postive mode 125m/z to 1500m/z Mass Range 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sequence: Glu-d[TT] 
Molecular Formula: [C25H37N6O14P2+] 
Expected m/z: 338.10 
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Sequence: Glu-d[TTC] 
Molecular Formula: [C34H45N9O20P22-]2H+ 
Expected m/z: 963.24 
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Sequence: Glu-d[TTC] 
Molecular Formula: 
[C34H41N9O20P26-] 2NH4++ 2K+ 
Expected m/z: 535.60 
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Sequence: Glu-d[TTCG] 
Molecular Formula: 
[C44H55N14O26P34-]2K+    
Expected m/z: 686.10 
 
m/z 
 
97 
 
 
 
 
Sequence: Glu-d[TTCGTAG] 
Molecular Formula: 
 [C74H90N27O44P69-] NH4+ 
Expected m/z: 249.60 
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Sequence: Glu-d[TT] 
Molecular Formula: 
[C40H44N6O16P2-]    
 Expected m/z: 894.26 
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Sequence: Glu-d[TTC] 
Molecular Formula: 
[C49H54N9O22P23-]2K+ 
Expected m/z: 1260.21 
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Sequence: Glu-d[TTCG] 
Molecular Formula: 
[C59H64N14O28P35-]4K+ 
Expected m/z: 1665.18 
Molecular Formula 
[C59H66N14O28P33-]Na+ 
Expected m/z: 767.16 
 
 
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sequence: Glu-d[TTCGTAGT] 
Molecular Formula: 
[C99H113N28O53P77-]3K+H+ 
Expected m/z: 958.80 
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Sequence: Fmoc-AK 
Molecular Formula: 
[C24H31N4O4+] 
Expected m/z: 439.54 
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Sequence: Fmoc-FAK 
Molecular Formula: 
[C33H40N5O5+] 
Expected m/z: 586.30 
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Sequence: Fmoc-KFAK 
Molecular Formula: 
[C39H52N7O6+] 
Expected m/z: 714.40 
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Sequence: Fmoc-KFAKK 
Molecular Formula: 
[C45H64N9O7+] 
Expected m/z: 842.49 
+2 
+3 
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Sequence: Fmoc-FAKFAKK 
Molecular Formula: 
[C57H78N11O9+] 
Expected m/z: 1060.60 
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Sequence: Fmoc- AKKFAKFAKKFAK 
Molecular Formula: 
[C90H133N20O15+] 
Expected m/z: 1734.03 
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Sequence: Fmoc- AKFAKKFAKFAKKFAK 
Molecular Formula: 
[C108H159N24O18+] 
Expected m/z: 2080.23 
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Sequence: Hex-KFAKFAKKFAKFAKKFAK 
Molecular Formula: 
[C114H176N27O19+] 
Expected m/z: 2227.36 
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APPENDIX B: SELECTED 1H, 13C NMR AND LC-MS SPECTRA FOR PEPTOID SIDE CHAINS 
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HPLC-MS SPECTRUM 3.1a 
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1H NMR SPECTRUM 3.1a 
 
13C NMR SPECTRUM 3.1a 
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HPLC-MS SPECTRUM 3.1c 
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1H NMR SPECTRUM 3.1c 
13C NMR SPECTRUM 3.1c 
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1H NMR SPECTRUM 3.2c 
13C NMR SPECTRUM 3.2c 
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13C NMR SPECTRUM 3.1d 
1H NMR SPECTRUM 3.1d 
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1H NMR SPECTRUM 3.2e 
13C NMR SPECTRUM 3.2e 
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HPLC-MS SPECTRUM 3.3e 
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1H NMR SPECTRUM 3.3e 
13C NMR SPECTRUM 3.3e 
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HPLC-MS SPECTRUM 3.4e 
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1H NMR SPECTRUM 3.4e 
13C NMR SPECTRUM 3.4e 
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HPLC-MS SPECTRUM 3.5e 
123 
 
 
 
13C NMR SPECTRUM 3.5e 
1H NMR SPECTRUM 3.5e 
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HPLC-MS SPECTRUM 3.1f 
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1H NMR SPECTRUM 3.1f 
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1H NMR SPECTRUM 3.2f 
13C NMR SPECTRUM 3.2f 
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HPLC-MS SPECTRUM 3.3f 
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1H NMR SPECTRUM 3.3f 
13C NMR SPECTRUM 3.3f 
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HPLC-MS SPECTRUM 3.4f 
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1H NMR SPECTRUM 3.4f 
13C NMR SPECTRUM 3.4f 
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HPLC-MS SPECTRUM 3.5f 
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1H NMR SPECTRUM 3.5f 
13C NMR SPECTRUM 3.5f 
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1H NMR SPECTRUM 3.6e 
13C NMR SPECTRUM 3.6e 
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1H NMR SPECTRUM 3.7a 
13C NMR SPECTRUM 3.7a 
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1H NMR SPECTRUM 3.8a 
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HPLC-MS SPECTRUM 3.9a 
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1H NMR SPECTRUM 3.9a 
13C NMR SPECTRUM 3.9a 
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HLPC-MS SPECTRUM 3.9b 
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1H NMR SPECTRUM 3.9b 
13C NMR SPECTRUM 3.9b 
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HPLC-MS SPECTRUM 3.9c 
141 
 
 
 
1H NMR SPECTRUM 3.9c 
13C NMR SPECTRUM 3.9c 
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APPENDIX C: 1H, AND 13C NMR OF FLUORESCENCE STANDARD REAGENT 
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1H NMR SPECTRUM 4.6 
13C NMR SPECTRUM 6.4 
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